Formulation and Evaluation of a Medicated Nail Lacquer for the Treatment of Onychomycosis by Aswani, V M
    FORMULATION AND EVALUATION OF A MEDICATED NAIL  
LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS 
 
Dissertation work submitted to 
The Tamilnadu  Dr.M.G.R.  Medical  University ,Chennai 
In partial Fulfillment for the award of degree of 
   
MASTER OF PHARMACY 
IN 
PHARMACEUTICS 
                                                     Submitted by 
ASWANI V M 
                                                           Reg NO.261310753 
Under the guidance of 
Dr. R.MANAVALAN, M.pharm, PhD 
Professor & Head 
Department of Pharmaceutics 
R.V.S College of pharmaceutical Sciences 
Sulur,Coimbatore 
 
(October 2015) 
DEPARTMENT OF PHARMACEUTICS 
       R.V.S COLLEGE OF PHARMACEUTICAL SCIENCES 
 SULUR, COIMBATORE-641 402, TAMIL NADU. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Certificates 
 
 
 
Evaluation Certificate 
 
Dissertation title             :  FORMULATION AND EVALUATION OF A 
                                                   MEDICATED   NAIL LACQUER FOR THE   
                                                   TREATMENT OF   ONYCHOMYCOSIS        
Name of the Candidate : ASWANI V M 
Course of study             :    Master of Pharmacy in Pharmaceutics, 
Institution Name            :    R V S College of Pharmaceutical Sciences, 
                                            Sulur, Coimbatore- 641 402 
 
 
 
 
 
 
 
 
INTERNAL EXAMINER                                 EXTERNAL EXAMINER   
 
 
 
PLACE: Coimbatoore 
DATE: 
 
Certificate 
                     This is to certify that the dissertation work entitled 
“FORMULATION AND EVALUATION OF A MEDICATED NAIL 
LACQUER FOR THE TREATMENT OF ONYCHOMYCOSIS “ is a bonafide 
work done by Aswani V M, RVS college of Pharmaceutical Sciences, Sulur, 
Coimbatore, for the partial fulfillment of the University rules and regulations for the 
award of Master of Pharmacy in Pharmaceutics under my guidance and supervision 
during the academic year 2015-16. 
 
 
Dr.R. MANAVALAN, M.pharm, PhD 
 Professor and  Head 
Department of Pharmaceutics 
R.V.S College of pharmaceutical Sciences 
Sulur, Coimbatore-641 402 
 
 
 
Dr.R.VENKATANARAYANAN,M.Pharm,PhD 
Principal 
R.V.S College of  Pharmaceutical  Sciences 
Sulur, Coimbatore-641 402 
 
 
Certificate 
                  
                  This is to certify that the dissertation work entitled  “FORMULATION 
AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE 
TREATMENT OF ONYCHOMYCOSIS“ is  a bonafide work done  by      Aswani 
V M under my direct guidance for the partial fulfillment of the award of degree of 
Master of Pharmacy in Pharmaceutics, RVS college of Pharmaceutical Sciences, 
Sulur, Coimbatore, affiliated to The Tamil nadu Dr.M.G.R Medical University 
,Chennai. 
 
 
 
 
Dr. R. MANAVALAN, M.pharm, PhD 
Professor and  Head 
Department of Pharmaceutics 
R.V.S College of  Pharmaceutical  Sciences 
Sulur, Coimbatore-641 402 
Place: Coimbatoore  
Date: 
 
 
 
Certificate 
                This is to certify that the dissertation work entitled “FORMULATION 
AND EVALUATION OF A MEDICATED NAIL LACQUER FOR THE 
TREATMENT OF ONYCHOMYCOSIS“ is a bonafide work done by        
 Aswani V M  under the  guidance  of under the guidance of Dr. R. 
MANAVALAN,  M -Pharm,Ph.D in the department of pharmaceutics,in the partial 
fulfillment of the awsard of degree of Master of Pharmacy in Pharmaceutics,R V S  
College of Pharmaceutical Sciences,Sulur,Coimbatoore,affiliated to the Tamilnadu 
Dr.M.G.R Medical University,chennai. 
 
 
 
 
 
     Dr.R.VENKATANARAYANAN,M.Pharm,PhD 
Principal 
R.V.S College of Pharmaceutical Sciences 
Sulur,Coimbatore. 
 
 
 
 
 
 
 
  
  
ACKNOWLEDGEMENT 
In the name of God, The Most Gracious ,The Most Merciful… 
At the very outset,I thank my Lord for His Blessing and support in completing this 
project work. 
                         In the first place, I would like to record my sincere and heartfelt 
gratitude to my Institution Guide Dr.R.Manavalan, M-Pharm, Ph.D ,Professor and 
head,RVS college of Pharmaceutical Sciences,Sulur,Coimbatore for her 
supervision,advice and inspiring guidance throughout my dissertation work. Above all, 
she provided me unflinching encouragement and support. 
                                Let me sincerely thank Dr. R. Venkatanarayanan , Professor and 
Principal, RVS  college of Pharmaceutical Sciences, Sulur, Coimbatore for his 
inspirations and being a great facilitator. 
                                 Let me express my sincere gratitude to Mr. Barish for his 
meticulous guidance and encouragement provided to me for the completion of my 
dissertation work. 
                               Let me express my sincere thanks to all the staffs in Hikma herbs 
Pvt.Ltd. and special thanks to my industrial guide Mr. Vipin K V. 
                             Let me express my sincere thanks to my classmates and to all my 
well-wishers without whose  inspiration and suggestions, my work would have been 
incomplete. 
                            Above all,I dedicate myself for  the constant love and encouragement 
given to me by my beloved parents who deserve the credit of success in whatever work 
I did. 
ASWANI V M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Abstract 
 
 
 
ABSTRACT 
                  Onychomycosis (also known as dermatophytic onychomycosis or Tinea 
unguium is a fungal infection of the nail. The causative pathogens of onychomycosis 
include dermatophytes, Candida, and nondermatophytic molds. In the present work, a 
medicated antifungal nail lacquer of Miconazole nitrate has been developed. The 
objective of the study was to deliver a sustained release of Miconazole nitrate over 
extended period of time up to 48 hours, and hence reduce the frequency of 
administration. This was expected to improve clinical efficacy and also improve the 
patient compliance. The nail lacquer formulation were prepared by simple mixing and 
analyzed for non -volatile content, gloss, smoothness to flow, drug diffusion studies, 
drug content estimation, anti -microbial studies. Among all formulation, nail lacquer 
prepared with 2% Miconazole nitrate, 6% nitrocellulose, 1% ethyl cellulose, 15 % 
salicylic acid, 10% propylene glycol and 10% 2-H- β-CD exhibited good non- volatile 
content, drug release, drug content estimation and zone of inhibition. The drug release 
could be extended up to 48 hour  and a complete release of 98.12% was observed. FTIR 
studies reveled that drug and excipients are compatible. Accelerated stability study of 
selected optimized formulation, F11 was done as per ICH guidelines for 1 month at 
40±20C, which revealed that no significant change with respect to the initial 
characteristics was observed. Formulation and usage of these systems are considered to 
be safe, without any complication. So we can conclude that the antifungal nail lacquer 
may be one of the novel dosage forms that can revolutionize the pharmaceutical and 
health care sector.  
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1.INTRODUCTION 
 
Over the last decades the treatment of illness has been accomplished by 
administrating drugs to human body via various routes namely oral, parental, topical, 
inhalation etc. Every medical condition demands an accurate and appropriate treatment. 
As a matter of fact, the thought of resolving the patient’s disease with least harm done 
to the patient’s health is said to be the basic goal of any therapy. Moreover a good 
treatment technique necessitates thorough knowledge of pharmacokinetics and 
pharmacodynamics of the intended drug. Hence we struggle day to day relentlessly to 
research and better our techniques and technology to develop with the best mode of 
treatment ensuring fast recovery as well as assuring safety of the patient. 
Human nails do not have only protective and decorative role, but can 
also be considered as an alternative pathway for drug delivery, especially in nail 
diseases such as onychomycosis or psoriasis. These nail diseases are widely spread in 
the population, particularly among elderly and immune-compromised patients. 
Although the architecture and composition of the nail plate severely limits penetration 
of drugs and in addition to that only a fraction of topical drug penetrates across the nail, 
oral therapies are accompanied by systemic side effects and drug interactions. For the 
successful treatment of nail disease the applied active drug must permeate through the 
dense keratinized nail plate and reach deeper layers, the nail bed and the nail matrix 1. 
The inadequate research and knowledge regarding the properties of keratinized nail 
plate, the nail bed and the nail matrix caused a lesser focus on ungual system. 
                            Horny structure nail plate is responsible for penetration of drug across 
it. As it is hard enough the penetration becomes difficult, only a fraction of topical drug 
penetrates across it. Hence the effective therapeutic concentration is not achieved. The 
nail plate may appear abnormal as a result of decreased glow. It is due to the  
involvement of nail bed, reduction of blood supply, physical or chemical features of 
nail bed. As a result variety of diseases occurs. These diseases can be cured by 
achieving desired therapeutic concentration of drug by nail drug delivery system.2 
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 Major challenges of drug delivery to the nail (ungual drug delivery), with the lack of 
understanding of both the barrier properties of the nail and formulations to achieve 
enhanced ungual delivery restricting the efficiency of topical treatments for nail 
disorders. And also suffer from low patient compliance due to the long treatment 
periods (up to 4‐8 months) which are required. 
However, existing oral formulations typically contain large doses of 
active ingredients and also require long treatment, creating the potential for systemic 
toxicity especially in the liver. Thus, developing more effective methods for nail drug 
delivery is an important objective for the pharmaceutical industry.3 
     1.1 STRUCTURE OF THE HUMAN NAIL4 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure of human nail 
          The human nail consists of  
 Nail matrix or the root of the nail 
 Nail bed 
 Eponychium or cuticle 
 Paronychium 
 Hyponychium 
 Nail plate 
 Lunula 5 
Introduction 
 
RVS College of Pharmaceutical Sciences Page 3 
 
 
 
a) Nail Root. 
          The root of the fingernail is also known as the germinal matrix. This portion of 
the nail is actually beneath the skin behind the fingernail and extends several 
millimeters into the finger. The fingernail root produces most of the volume of the nail 
and the nail bed. This portion of the nail does not have any melanocytes, or melanin 
producing cells. The edge of the germinal matrix is seen as a white, crescent shaped 
structure called the LUNULA. 
b) Nail Bed. 
           The nail bed is part of the nail matrix called the sterile matrix. It extends from 
the edge of the germinal matrix (lunula) to the hyponychium. It is a thin, soft, 
noncornified epithelium, connected with the ventral layer of the nail plate and 
underlying papillary dermis and contains the blood vessels, nerves, and melanocytes, or 
melanin-producing cells. As the nail is produced by the root, it streams down along the 
nail bed, which adds material to the undersurface of the nail making it thicker. 
c) Cuticle / Eponychium 
          The cuticle of the fingernail is also called the eponychium. The cuticle is situated 
between the skin of the finger and the nail plate fusing these structures together and 
providing a waterproof barrier. 
d) Perionychium 
            The perionychium is the skin that overlies the nail plate on its sides. It is also 
known as the paronychial edge. The perionychium is the site of hangnails, ingrown 
nails, and an infection of the skin called paronychia. 
e) Hyponychium 
               The hyponychium is the area between the nail plate and the fingertip. It is the 
junction between the free edge of the nail and the skin of the fingertip, also providing a 
waterproof barrier. 
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f) Lunula 
                 The edge of the germinal matrix is seen as a white, crescent shaped 
structure called the LUNULA. 
Nail Growth 
                Nails grow all the time, but their rate of growth slows down with age and 
poor circulation. Fingernails grow faster than toenails at a rate of 3mm per month. It 
takes 6 months for a nail to grow from the root to the free edge. Toenails grow about 1 
mm per month and take 12-18 months to be completely replaced. 
                Thickness of finger nail is 0.25 ‐ 0.6 mm and that of toe nail is up to 1.3mm. 
The nail plate is made up of approximately 25 layers of dead keratinized, flattened cells. 
They are strongly bound to one another via numerous intercellular links, membrane‐
coating granules and desmosomes. Desmosomes are cell structures, specialized for cell‐
to‐cell adhesion and randomly arranged on the lateral sides of plasma membranes. The 
fingernail has a three‐layer structure (from outer to inner) – 
 dorsal 
 intermediate and 
  Ventral layers with a thickness ratio of approximately 3:5:2,respectively. 
 
The dorsal outer layer is dense and hard, consisting of cornified keratin only a few cells 
thick (approximately 200 μ). The intermediate layer, in contrast to the dorsal layer, 
shows highly fibrous structure oriented in a direction perpendicular to the direction of 
nail growth and constitutes roughly 75% of the plate’s thickness. The ventral layer is 
very thin and consists of a few layers of cells which connect the nail plate to the nail 
bed below. 
1.2 ANATOMY OF HUMAN NAIL6 
        The human nail plate consists of three layers; the dorsal and intermediate layer 
derived from the matrix and the ventral layer from nail bed. The intermediate layer is 
three - quarter of the whole nail thickness & consists of the soft keratin. The upper 
layer, dorsal, is only a few cell layer thick but consists of hard keratin, with relatively 
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high sulphur content, mainly in the form of amino acids cysteine, which constitutes 
94% by weight of nail. The upper layer of the nail mainly diffuses into and through the 
nail plate. The ventral layer consists of soft hyponychial in which many pathological 
changes occur. Thus, in the treatment of these nail diseases, an effective drug 
concentration in the ventral nail plate would be of great importance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Nail Anatomy6 
 
                               Nail growth is greatest in childhood and decrease slowly with aging. 
Due to pressure from posterior nail fold grows forward instead of upward. Nail growth 
is also affected by local disturbances in the nail fold or by abnormal keratinization of 
the nail plate. General or local factor may result in the development in the nail of 
thicken, ridging, pitting, discoloration, brittleness, splitting and even separation of nail 
from its bed (onycholysis). A transverse groove may result from severe illness. The 
changes in colour for a variety of reasons for instance white spots in the nail plate, 
which is seen 62% of normal people, is due to imperfect keratinization with retention of 
nuclear material. 
1.3   CHEMICAL PROPERTIES OF THE NAIL PLATE7 
 Low sulfur keratins embedded in an amorphous matrix of high -sulfur proteins 
rich in cysteine.  
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 Water content is  20%  
 
 If <18% = brittle 
 
 If >30% = opaque and soft  
 
 Lipid content is <5%   mainly cholesterol  
 
 Trace inorganic elements:  
                        a)  Iron  
 
                        b) Zinc  
 
                        c) Calcium  
 
 Nail keratins:  
 
                                   a) 80% of keratins are hard “hair-type” keratins  
 
                                   b) 20% of keratins are soft “skin-type” keratins  
 
1.4 NAIL DISEASES 
The nail plate may appear abnormal as a result of, a congenital defect, 
disease of skin with involvement of the nail bed, systematic disease, reduction of blood 
supply, local trauma, tumors of the nail fold or nail bed, infection of the nail fold, 
infection of the nail plate. 
There are many nail diseases such as 
 A) Green-nail syndrome : An infection which is caused by Pseudomonas 7 
 B) Paronychia:  
1. Acute paronychia: Erythema, swelling and throbbing pain in the nail fold caused by 
bacterial infection, e.g. S. aureus and Group A streptococci.  
2. Chronic paronychia: Mostly occurs in patients whose hands are constantly in water 
with repeated minor trauma damaging the cuticle so that irritants can further damage 
the nail fold. Commonly becomes infected especially with C. albicans or Pseudomonas 
spp. (produces a green or black discoloration)8  
C) Parakeratosis pustulosa: Showing subungual hyperkeratosis and onycholysis 9, 10 
 
D) Nail Psoriasis: Scaly skin, the nail plate becomes pitted, dry and often crumbles and 
also appears red, orange or brown, with red spots in the lunula. 
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E) Yellow nail syndrome: A rare condition characterized by yellow nails with lack   
of cuticle, grows slowly, and is loose or detached associated with onycholysis in one or 
more nails11.  
 F) Onychomycosis 2, 3:  Onychomycosis accounts for one third of integumentary 
fungal infections and one half of all nail disease. Tinea unguium is more than a 
cosmetic problem, although persons with this infection are often embarrassed about 
their nail disfigurement. Because it can sometimes limit mobility, onychomycosis may 
indirectly decrease peripheral circulation, thereby worsening conditions such as venous 
stasis and diabetic foot ulcers. Fungal infections of the nails can also spread to other 
areas of the body and, perhaps, to other persons12,14. 
1.5  ETIOLOGY13 
The causative pathogens of onychomycosis include dermatophytes, 
Candida, and nondermatophytic molds. Dermatophytes are the fungi most commonly 
responsible for onychomycosis in the temperate western countries, while Candida and 
nondermatophytic molds are more frequently involved in the tropics and subtropics 
with hot and humid climate. 
 
Dermatophytes 
                             Trichophyton rubrum is  the  most common dermatophyte involved    
in onychomycosis. Other dermatophytes that may be involved are Trichophyton 
interdigitale, Epidermophyton floccossum, Trichophyton violaceum, Mycosporum 
gypseum, Trichophyton tonsurans and Trichophyton soudanense. 
Other pathogens 
    Other causative pathogens include Candida and non dermatophytic molds, in 
particular members of the mold generation Scytalidium (name recently changed to 
Neoscytalidium), Scopulariopsis. Candida mainly causes fingernail onychomycosis in 
people whose hands are often submerged in water. Scytalidium mainly effects people in 
the tropics, though it persists if they later move to areas of temperate climate. 
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Risk factors: 
Risk factors for Onychomycosis include family history, increasing age, 
poor health, prior trauma, warm climate, participation in fitness activities, 
immunosuppression (e.g., HIV, drug induced), communal bathing, and occlusive 
footwear. 
 
1.6 CLASSIFICATION OF ONYCHOMYCOSIS 2, 3 
 
A. Distal Subungual Onychomycosis 
                 
                 The most common form of Tinea unguium is distal subungual. Distal 
subungual onychomycosis may develop in the toenails, fingernails or both. The 
infection is usually caused by Trichophyton rubrum, which invades the nail bed and the 
underside of the nail plate, beginning at the hyponychium and then migrating 
proximally through the underlying nail matrix. Susceptibility to distal superficial 
onychomycosis may occur in an autosomal dominant pattern within families (5A). 
 
 B.  White Superficial Onychomycosis 
 
White superficial onychomycosis accounts for only 10 percent of 
onychomycosis cases. White superficial onychomycosis is caused by certain fungi that 
directly invade the superficial layers of the nail plate and form well-delineated opaque 
“white islands” on the plate. As the disease progresses, these patches coalesce to 
involve the entire nail plate. The nail becomes rough, soft and crumbly. The most 
common causative agent is Trichophyton mentagrophytes. This type of onychomycosis 
can be treated with topical antifungal drugs alone. (5B) 
 
C. Proximal Subungual Onychomycosis 
                   Proximal subungual onychomycosis occurs when the infecting organism, 
usually T. rubrum, invades the nail unit through the proximal nail fold, penetrates the 
newly formed nail plate and then migrates distally. Fingernails and toenails are equally 
affected. This form of onychomycosis usually occurs in immune compromised persons 
and is considered a clinical marker of human immunodeficiency virus infection.  
Introduction 
 
RVS College of Pharmaceutical Sciences Page 9 
 
 
Proximal subungual onychomycosis can also arise secondary to local trauma (5C). 
  
D. Candidal Onychomycosis 
Candida onychomycosis can be divided into three general categories.  
(i) Infection beginning as a paronychia (infection of the structures surrounding the 
nail; also called a “whitlow”), the most common type of Candida onychomycosis. 
(ii) Patients with chronic mucocutaneous candidiasis are at risk for the second type of 
Candida onychomycosis, called Candida granuloma, which accounts for less than 1% of 
onychomycosis. This condition is seen in immune compromised patients and involves 
direct invasion of the nail plate.  
(ii) Candida onycholysis can occur when the nail plate has separated from the nail bed. 
Distal subungual hyperkeratosis can be seen as a yellowish gray mass lifts off the nail 
plate.  
 
E.  Total Dystrophic Onychomycosis 
                            Total dystrophic onychomycosis may be the end result of any of the 
four main   forms of onychomycosis (5D). 
 
 
 
 
 
 
 
 
 
 
Figure 3: Classification of onychomycosis 
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1.7 CLINICAL FEATURES13 
 
                                      The nail plate can have a thickened, yellow or cloudy 
appearance. The nails can become rough and crumbly, or can separate from the nail 
bed. There is usually no pain or other bodily symptoms, unless the disease is severe. 
Dermatophytids are fungus-free skin lesions that sometimes form as a result of a fungus 
infection in another part of the body.  
                   This could take the form of a rash or itch in an area of the body that is not 
infected with the fungus. Dermatophytids can be thought of as an allergic reaction to 
the fungus. People with onychomycosis may experience significant psychosocial 
problems due to the appearance of the nail. This is particularly increased when 
fingernails are affected. 
1.8 DIAGNOSIS OF ONYCHOMYCOSIS14, 15, 16 
Conventional methods for identifying fungal organisms in the nail plate of patients 
with onychomycosis (OM) include direct microscopy (after potassium hydroxide 
solution incubation), fungal culture, and histopathology (using Periodic Acid Schiff 
[PAS] stain).  Surgical pathology testing (of the subungual nail bed and/or the nail 
plate) using PAS stain is the current gold standard (approaching 100% sensitivity) for 
the diagnosis of OM. Newer methods for diagnosing OM include polymerase chain 
reaction (which has a very high specificity), optical coherence tomography, confocal 
laser scan microscopy, matrix- assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS), and phase contrast hard x-ray microscopy. 
Confirmation of observations and availability and cost must be considered before these 
newer methods for diagnosing OM can be incorporated in clinical practice. 
 
1.9 TREATMENTS OF ONYCHOMYCOSIS17, 18, 19 
 
                          Several modalities can be used for the treatment of onychomycosis 
topical therapy, systemic therapy, combination therapy, and nail removal. Patients 
greater than 55 years of age may have a higher rate of relapse. 
 
Introduction 
 
RVS College of Pharmaceutical Sciences Page 11 
 
 
1.9.1 Nail removal, avulsion 
                    
                     Removal of diseased nails can be used as an adjunctive therapy but not as 
the sole therapy for onychomycosis. Surgical nail avulsion is rarely used to treat 
onychomycosis in diabetic patients because of their increased risk for secondary 
infections, gangrene, and poor wound healing. However, in severe or refractory cases, 
nail removal may be used. It may also be used when oral therapy is contraindicated or 
ineffective. 
Demerits of surgical treatment 
 
Surgical nail avulsion can bring severe pain and further trauma to the 
patient. Surgical removal of the nail plate (fingernail or toenail) is not effective 
treatment of onychomycosis without additional therapy. This procedure should be 
considered only an adjunctive treatment combined with oral medical therapy. 
     
 1.9.2 Oral therapy 
Many studies have evaluated systemic treatments for onychomycosis in 
the general population. Oral agents are absorbed via the circulation through the nail bed 
and take nearly 7 days to reach minimal inhibitory concentration (MIC). Once 
administration of the drug is discontinued, it can remain active in the nail for up to 90 
days, and the nail does not need to be completely clear before the medication is 
stopped.  
Griseofulvin was the standard oral therapy for onychomycosis for more 
than 30 years. However, it has a narrow therapeutic window and significant adverse 
reactions. It also has several interactions with other drugs and is active only against 
dermatophytes, with a cure rate of less than 40%. For these reasons, it is rarely used 
today to treat onychomycosis. 
The imidazole class of medications is active against most of the 
organisms that cause onychomycosis. Ketoconazole is slightly more efficacious than 
Griseofulvin but also has many adverse effects and drug interactions.  
It is rarely used to treat onychomycosis today. Fluconazole, 300mg once 
a week for 6 months, is more efficacious and has been shown to be safe. Itraconazole, a 
triazole antifungal, binds more specifically to fungal cytochrome P-450 than other 
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azoles, reducing the incidence of side effects. 
 It is active against dermatophytes Candida and Aspergillus but not 
Scytalidium, a mold. Because of the high cost of Itraconazole, a pulse regiment has 
been formulated and tested. Pulse treatment involves using 200 mg twice daily for 1 
week during each of 2 months in fingernails and 3 months in toenails. Pulse therapy has 
been reported to be just as effective as continuous therapy with fewer adverse events 
and half the cost. Terbinafine, 250 mg once daily for 3 months, has been shown to 
achieve a mycological cure rate of 82% in toenail onychomycosis and 71% in fingernail 
onychomycosis. 
  
 
 
Table No.1: Treatment and mycological cure rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disadvantages of oral therapy 
 
                               Oral therapy is followed by some disadvantages such as drug 
interactions, contraindications, side effects, high cost of medication, and a long duration 
of treatment. Moreover, systemic use of azoles can be linked to hepatotoxicity, 
especially during prolonged use.  
1.9.3  Topical therapy 
 
There are three classes of topical antifungal creams: polyenes 
(e.g.Nystatin), imidazoles (e.g.Clotrimazole), and allylamines- benzylamines 
(e.g.Terbinafine).  
 
    
       Treatment 
 
Mycological cure rates 
 
Terbinafine(continuous)  76 %( ±4%) 
 
Itraconazole(pulse-dose)  63 %( ±7%) 
 
Itraconazole(continuous)  59 %( ±5%) 
 
Griseofulvin 
 
40 %( ±6%) 
 
Fluconazole 
 
48 %( ±5%) 
 
Miconazole 
 
53.4 %( ±7%) 
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                 All three are active against Candida, but only imidazoles and allylamines 
benzylamines are active against dermatophytes. In general, topical therapy is not 
adequate for clearing nail infections, probably because of inadequate penetration of the 
medication into the affected tissues and nail bed. The exception to this is superficial 
white onychomycosis, which is easily treated with a topical agent because the organism 
grows on the upper nail plate rather than in the nail bed. Antifungal nail lacquers are 
available for treating onychomycosis and penetrate the nail better than creams and gels. 
One lacquer contains the active ingredient Amorolfine, which is in a new class of 
antifungals, the morpholines. Another lacquer contains Ciclopirox, which has a broader 
spectrum of activity. Nail lacquers are applied daily for 48 weeks and once-weekly 
removal with nail polish remover is required. 
 
Demerits of topical therapy 
 
 They should be reserved for mild distal disease in up to two nails, or for superficial 
white onychomycosis, or where there are contra-indications to systemic therapy.  
 Treatment should be given daily for six months to one year  
 Topical therapy  often fails due to poor penetration through nail plate and provide less 
contact time  
 
To overcome the disadvantages of conventional topical drug delivery system, a noval 
formulation called medicated nail lacquers has been formulated and was reported to be 
a potential drug delivery system for the treatment of Onychomycosis.  
The Food and Drug Administration (FDA) approved Ciclopirox nail lacquer for the 
treatment of mild to moderate onychomycosis caused by Tinea rubrum without 
involvement of the lunula 20, 21. 
1.10 NAIL LACQUER3, 19, 20, 21 
 
Nail polish or nail varnish is applied to human fingernails or toenails to 
decorate and/or protect the nail plate. Conventional nail lacquers have been used as 
cosmetics since a long time for beautification and protection of nails. 
 Topical nail preparations like lacquers, enamel and varnish are an integral 
part of today’s beauty treatments. It protects the nail plate, but more importantly it 
enhances their beauty, imparting color and luster. 
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A model nail lacquer should have the following properties: 
 
 It should be harmless to skin and nails.  
 It should be convenient and easy to apply.  
 It should be stable on storage  
 It should form a satisfactory film on nails.  
To achieve satisfactory film it should have the following characteristics: 
 
 It should have good wetting and flow properties so that the film formed is even.  
 
 It should have uniform colour.  
 
 It should have good gloss.  
 
 It should have good adhesive properties.  
 
 It should have sufficient flexibility so that it does not crack or become brittle.  
 
 It should have sufficient hard surface which is resistant to impact and scratch.  
 
 It should have reasonable drying time (1-2 minutes) without developing bloom.  
 
 It should be able to maintain the above-mentioned properties for a reasonable time 
(about 1 week).  
 
 
Constituents of nail lacquer 
 
The basic nail varnish consists of solvents, film forming polymers, 
resins which enable the film to adhere to nail plate and convey shining to the film, 
plasticizers which give flexibility and durability to the film, colouring agents and 
suspending agents. 
 
a. Film formers 
 
A number of film forming substances have been suggested for nail 
enamels. These include nitrocellulose, cellulose acetate, cellulose acetate butylate, ethyl 
cellulose, vinyl polymers and various polymers of methacrylate. 
 
b. Resins 
 
Resins impart adhesion and improve gloss. Commonly used resins are 
Santolite MHP and Santolite MS 80%. They are claimed to increase moisture 
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resistance. They are soluble in majority of solvents. 
 
c. Plasticizers 
 
Plasticizers impart flexibility and adhesive properties to the film. There 
are two types of plasticizers, solvent and non-solvent plasticizers. The amount of 
plasticizers which can be used in nail lacquers varies widely and may vary from 25% to 
50% of film former. The amount depends on flexibility of film required. Dibutyl 
phthalate is most widely used plasticizer. 
 
d. Solvents 
 
Although evaporation characteristics are of prime importance in nail 
lacquers, but rapid rate of evaporation causes a poor flow of enamel resulting in uneven 
and streaky application. Solvents are generally classified according to their boiling 
points. 
1) Low boiling point solvents: e.g. Ethyl ether, Acetone, Ethyl alcohol etc.  
 
2) Medium boiling point solvents: e.g. N-Butyl acetate, n-Butyl alcohol etc.  
 
3) High boiling point solvents: eg. Ethyl lactate. Alcohols, particularly ethyl, 
isopropyl and butyl are very efficient diluents. 
 
e.  Pigments 
 
Pigments used in nail enamels should have the same properties as 
required in other cosmetics. commonly used pigments are titanium dioxide, yellow iron 
oxide, red iron oxide, etc. 
f. Suspending agents 
 
            Insoluble pigments and iridescent materials have tendency to settle. Therefore to 
avoid this suspending agents such as colloidal clays like bentonite can be used. 
            In recent past, medicated lacquers specially designed for the nail diseases, strike 
the formulation field. Nail diseases like onychomycosis, nail psoriasis, yellow nail 
syndrome, paronychia and many more, being cured successfully using medicated 
lacquers. This avoids the oral toxicity of anti-fungal drugs and provides longer contact 
time at the site of action. This systemic review covers the anatomy of a human nail, 
diseases related to nail plate, the formulations designed for nail application and some  
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techniques used to enhance the topical bioavailability of the drugs across the nail, latest 
trends in drug delivery across the nail. 
           Nail lacquer can be used as a drug delivery system for the drugs that exhibit poor 
oral bioavailability. The topical formulations conventionally used in dermatology 
(creams, oil-based lotions, powders) are not specifically adapted to the nail since they 
are readily removed by rubbing, whipping, and washing; and their impermeance at the 
site of application readily accounts for their inefficacy. 
           Medicated nail lacquers are formulations that are used for ungual drug delivery 
system for maximal antifungal efficacy. It has been reported that the film on the nail 
surface acts as a drug depot that permits optimized and sustained diffusion across the 
nail and leads to continuous penetration of active principle to high tissue concentration 
required for the efficacy for the treatment of onychomycosis. 
           The present invention relates to a formulation for treating fungal infections. 
More specifically, this formulation is a topical formulation for use on fingernails and 
toenails. Many people have fingernails or toenails with fungus underneath. Still others 
have nails that are extremely thick even approaching approximately one inch in 
thickness. Still others have yellowed or discolored nails.  
           Some have combinations of the above‐mentioned conditions. Some medications 
available for treating these unsightly conditions are not able to kill fungal infections 
underneath the nail because they are not able to penetrate the nail. 
           Still other medications cause the nail to become brittle. In addition, other 
medications simply do not work. Therefore, many people are unable to remove these 
unsightly conditions. In order to overcome the disadvantages of medications currently 
available, a formulation that is able to penetrate the nail to kill fungus without 
permanently damaging the nail is needed. 
          This formulation should be able to be applied topically. The human nail is an 
excellent barrier against the ingress of foreign material, but as a consequence it also 
prevents effective topical treatment of ungula disorders such as onychomycosis. 
        When infection resides in the nail plate, nail bed, or both, therapeutic antimicrobial 
drug concentrations must be achieved in the nail bed for treatment to be effective. 
However, this is difficult to achieve because the permeation of agents into the nail is 
low.  
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Permeation occurs via passive diffusion with the rate determined by the 
physicochemical properties of the compound. Unfortunately, the most efficacious 
treatments for nail disorders do not penetrate the nail plate in sufficient amounts to be 
clinically effective. 
 
The common approach for enhancing nail drug delivery has been to use 
keratolytic and thiolytic agents. These agents are known to increase the permeability of 
nail matrix by chemical modification of keratin. However, their permeability 
enhancement potential is limited by the factors like penetrability of enhancer and the 
duration of its presence in the nail matrix might significantly influence the chemical 
modification of keratin. 
Topical monotherapy is considered less efficient in treating nail 
disorders such as onychomycosis due to poor trans‐nail bioavailability of drugs. 
 
1.11 ABSORPTION THROUGH NAIL 22 
 
Nail plate is approximately 0.25–0.6 mm, which is approximately 100-
fold thicker than the stratum corneum. In contrast to the stratum corneum, the nail plate 
behaves like a concentrated hydrogel rather than a lipophilic membrane. Hydration can 
affect the effective pore size of hydrogel and thus the transungual transport. Hydrated 
human nail plates behave like a hydrogel of high ionic strength to the polar & semi 
polar alcohols [6]. Moreover the nail is primarily enriched with highly disulfide-linked 
keratin. The nail selects for the penetration of small, hydrophilic molecules3. Most 
pharmaceutical agents are large and highly lipophilic, and are therefore unable to 
diffuse across the nail at therapeutic concentrations. Lipophilic vehicles and especially 
nail lacquers are more appropriate for topical application on the nail than aqueous 
systems because of their better adhesion23. Penetration through the nail plate follows 
first order kinetics after a lag-time of 400 hours. The course of penetration initially is 
membrane-controlled and later becomes a matrix-controlled process because of the 
membrane's greater permeability. 
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1.12 FACTORS INFLUENCING UNGUAL DRUG DELIVERY 23, 24 
 
 Molecular size of diffusing molecule 
 Hydrophilicity/lipophilicity of diffusing molecule 
 Nature of vehicle 
 pH of vehicle and solute charge 
 Presence of an intact dorsal layer 
 Binding of drug to keratin and other nail constituents 
 Presence of disease can alter the properties of nail 
 Thickness of the nail 
 
a. Molecular size of diffusing molecule 
 
Molecular size is inversely proportional to the penetration into the nail 
plate. It is harder for larger molecules to diffuse through the keratin network. The 
molecular weight of most of the antifungal agents is > 300 Dalton. Hence these drugs 
will have difficulty penetrating the nail plate which can be a reason for the poor clinical 
efficacy. 
 
b. Hydrophilicity/Lipophilicity of diffusing molecule 
 
On increasing lipophilicity of the diffusing alcohol molecule the 
permeability coefficient reduces until a certain point beyond which further increase in 
lipophilicity results in increased permeation. However, with the exception of methanol, 
the permeability coefficient of neat alcohols (absence of water) was approximately 5 
times smaller than the permeability coefficient of diluted alcohols. When an aqueous 
formulation is used; the nail swells as water is absorbed into the nail plates. As a result 
the keratin network expands leading to the formation of larger pores through which 
diffusing molecules can permeate more easily. 
 
  c.  Nature of vehicle 
                                   As the nail absorbs water, it swells. This swelling results in 
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increased distance between the keratin fibers and leads to the formation of larger pores 
through which permeating molecules can diffuse. This is due to hydrogel property of 
nail plate. On replacing water with a non-polar solvent, that does not hydrate the nail; 
the drug permeation into the nail plate is expected to reduce. Aqueous vehicles are not 
effective as lipophilic vehicles for topical application because they are easily washed / 
wiped off and do not adhere as well to the nail plate. 
          
          d. pH of vehicle and solute charge 
 
                         Uncharged species tend to permeate better than the charged ones. The 
pH of aqueous formulations influences the ionization of weakly acidic/basic drugs,  
 
which in turn has an effect on: 
 
 the drug’s hydrophilicity / hydrophobicity, 
 
 solubility in the drug formulation, 
 
 solubility in the nail plate and 
 
 Its interactions with the keratin matrix. 
 
 
e. Presence of an intact dorsal layer 
 
It is generally recognized that the very thin dorsal layer with its 
overlapping cells represents the greatest barrier to the drug penetration across the nail 
plate. If this layer is partially or totally removed e.g., by debridement or chemical 
etching with 30-40% phosphoric acid or use of keratinolytic enzymes, then drug 
permeability increases. 
 
       f.Binding of the drug to keratin and other nail constituents 
 
pH of keratin ranges around 5 and therefore is positively and negatively 
charged at pH below and above this value. It might bind or repel molecules depending 
on their charge. This can be one of the reasons of lower nail permeability of ionic 
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compounds. It has been shown that a number of drugs including Terbinafine and 
Amorolfine bind strongly to keratin, and can influence their respective antifungal 
activity. 
        g. Presence of disease can alter the properties of nail24 
 
Various nail conditions affect the nail very adversely. Conditions such as 
Onychogryposis is characterized by a thickened nail plate, Onychatrophia is an atrophy 
or wasting away of the nail plate, Tinea unguis of the nails, is characterized by nail 
thickening, deformity, and eventually results in nail plate loss. Pseudomonas can even 
cause the nail plate to lift from the nail bed. 
 
         h.Thickness of the nail - Greater the thickness, lower is the permeation of the drug    
          through the nail plate. 
 
1.13 PENETRATION THROUGH NAILS23 
 
The penetration of drug into nail is quite difficult due to various factors 
such as the molecular size of the drug, hydrophilicity, pH, solute charge. Consequently 
researches are currently being undertaken to design novel in vitro methods to assess the 
ability of compounds to penetrate the nail plate [13]. The goal of topical therapy for 
Onychomycosis is drug penetration into deep nail stratums at amounts above the 
minimal inhibitory concentration (MIC). Effective penetration still remains challenging 
as the nail is composed of approximately 25 layers of tightly bound keratinized cells 
which in comparison to stratum corneum is 100- fold thicker. 
          
         Different methods developed so far are: 
 
A. Chemical means  
 
B. Mechanical means  
 
C. Physical means 
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A.        Chemical methods to enhance nail penetration 
 
Chemically, drug permeation into the nail plate can be assisted by 
breaking the physical and chemical bonds responsible for the stability of nail keratin. 
This would destabilize the keratin, compromise the integrity of the nail barrier and 
allow penetration of drug molecules. 
Wang and Sun (1998), identified the disulphide, peptide, hydrogen and 
polar bonds in keratin that could potentially be targeted by chemical enhancers such as: 
 
                1)  Nail softening agents or Keratolytic enhancers 
 
                            Keratolytic  agents  such  as  (papain,  urea,  and  salicylic  acid)  
enhance the permeability of three imidazole antifungal drugs (Miconazole, 
Ketoconazole, and Itraconazole) Urea and salicylic acid hydrate and soften nail plates.  
 
Urea and salicylic acid also damage the surface of nail plates, resulting in a fractured 
surface. Effects of the physical enhancers were penetrant specific, but the use of a 
reducing agent followed by an oxidizing agent (Urea, H2O2) dramatically improved 
human nail penetration while reversing the application order of the physical enhancers 
was only mildly effective. Both nail physical enhancers are likely to function via 
disruption of keratin disulphide bonds and the associated formation of pores that 
provide more ‘open’ drug transport channels 
 
              2) Compounds containing sulfhydryl groups 
 
Compounds which contain sulfhydryl (SH) groups such as acetyl 
cysteine, cysteine, mercaptoethanol can reduce, thus cleave the disulphide bonds in nail 
proteins, as shown in the reaction sequence below: 
Nail-S-S-Nail + R-SH → 2 Nail – SH + R-S-S-R 
 
R represents a sulfydryl-containing compound.  
 
However, post-treatment barrier integrity studies demonstrated that 
changes induced in the nail keratin matrix by these effective chemical modifiers were 
irreversible. It is believed that these enhancers act by breaking disulphide bonds, which 
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are responsible for nail integrity thus producing structural changes in the nail plate. 
 
                3)  Keratinolytic enzymes 
 
Due to an abundance of keratin filaments, keratinic tissues like the 
Subcutaneous are effectively hydrolyzed by keratinase. It is hypothesized that 
keratinolytic enzymes may hydrolyze nail keratins, thereby weakening the nail barrier 
and enhancing ungual drug permeation. Keratinase act on both the intercellular matrix 
that holds the cells of the nail plate together and the dorsal nail corneocytes by 
corroding their surface. 
 
B. Mechanical means involves  
 
 
 
            1) Nail abrasion 
               Nail abrasion thins the nail plate, decreasing the fungal mass of onychomycosis 
and exposing the infected nail bed. 
 
 
2)  Nail avulsion 
 
 
Total nail avulsion and partial nail avulsion involve surgical removal of 
the entire nail plate or partial removal of the affected nail plate, and under local 
anesthesia. Keratolytic agents such as urea and salicylic acid soften the nail plate for 
avulsion. Urea or a combination of Urea and Salicylic acid has been used for 
nonsurgical avulsion. 
 
C. Physical means of enhancing drug permeation involves the use of agents that  
by delipidization or fluidization of the intracellular lipids in the nail plate can help in 
drug permeation.  
                       Some of the approaches have been used to resolve these barriers to drug 
delivery include:  
 
          1)  Iontophoresis 
 
Iontophoresis involves delivery of a compound across a membrane using 
an electric field (electromotive force). Drug diffusion through the hydrated keratin of a 
nail may be enhanced by iontophoresis. 
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           2)  Electroporation 
 
Electroporation is a method in which, with the application of an electric 
pulse of about 100–1,000 V/cm creates transient aqueous pores in the lipid bilayers 
making the solute particles permeable through it. 
 
  3)  Micro needle enhanced delivery systems 
 
Method using arrays of microscopic needles to open pores in the SC 
directly to the skin capillaries; also has the advantage of being too short to stimulate the 
pain fibers, thus facilitating drug permeation. 
           4)  Etching 
                     “Etching” results from surface-modifying chemical (e.g. Phosphoric acid) 
exposure, resulting in formation of profuse micro porosities.  
 
 
Presence of micro porosities improves “interpenetration and bonding of a polymeric 
delivery system and facilitation of interdiffusion of a therapeutic agent.” 
 
 5)  Carbon dioxide laser 
                   CO2 laser may result in positive. Here involves penetrating the nail plate 
with CO2 laser beam. This method is followed with daily topical antifungal treatment, 
penetrating laser-induced puncture holes. 
 
  6)  Hydration and occlusion 
Hydration may increase the pore size of nail matrix, enhancing 
transungual penetration. Additionally, hydrated nails are more elastic and permeable. 
Decreases in transonychial water loss, ceramide concentration, and water binding 
capacity may result from Onychomycosis. Occlusion may resolve these changes via 
reconstitution of water and lipid homeostatisis in dystrophic nails. 
           Other physical penetration enhancements - Lasers, Phonophoresis, Ultraviolet light. 
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Need of the study: 
 
    Onychomycosis is a chronic condition which requires long duration of 
treatment. Oral therapies are accompanied by systemic side effect, while topical therapy 
are limited by low permeation and restrictive barrier property of nail plate. Medicated 
nail lacquer after application leaves an occlusive film over the nail, which act as a drug 
depot from which sustained release of antifungal is provided for entire duration of 
therapy. Therefore in the present study an attempt to formulate an antifungal agent as a 
nail lacquer formulation has been tried out. Although Miconazole has been a widely 
used as antifungal, no work has been reported to improve the permeation of Miconazole 
nitrate from a nail lacquer formulation. The purpose of this study is to explore the 
potential of an ideal permeation enhancer in improving penetration of drug across nail 
plate and whereby could result in an enhancement of bioavailability of antifungal drug. 
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2. AIM AND OBJECTIVE 
 
Onychomycosis (tineaunguium) is a fungal infection of the nail bed or 
nail plate that accounts for approximately 50% of all nail diseases and is the most 
common disorder in adults. Onychomycosis though rarely life threatening, they can be 
very painful, discomfortable and disfiguring for the sufferer and may produce serious 
physical and occupational limitations, psychological and emotional effects, and affect 
quality of life. Deformed nails can lead to surrounding tissue damage and may promote 
secondary bacterial infection. Known methods for the treatment fall into three 
categories: 1. Removal of all or part of the affected nails 2.Oral / systemic therapy 
3.Topical/Ungual therapy. Creams, ointments, gels, solutions, lotions, foams, pastes etc 
are available dosage forms for topical delivery. Topical or oral therapy of nail diseases 
are also limited by poor permeability of the nail plate, oral toxicity of antifungal agents 
and provide longer contact time to the site of action. In recent past, medicated lacquers 
specially designed for nail diseases. The treatment of onychomycosis is a challenging 
task because of unique barrier properties of the nail plate which hampers the passage of 
antifungal drugs in a concentration required to eradicate the deeply seated causative 
fungi in the nail bed. In present investigation, an attempt will be done to explore the 
potential of 2-hydroxypropyl-β-cyclodextrin (2-HP-β-CD) as an effective and nail 
friendly transungual drug permeation enhancer for Miconazole nitrate, a poorly water 
soluble drug. 2-HP-β-CD is expected to improve the hydration of nail plates and 
thereby increasing solubility of Miconazole nitrate which could further enhance its 
permeation across nail plate.  
 
2.1 Objective of the study 
                   The purpose of the present investigation is to formulate and evaluate an 
antifungal nail lacquer for treatment of onychomycosis. A nail lacquer will be 
formulated, consisting of antifungal drug Miconazole nitrate, film forming polymers 
like nitrocellulose, plasticizer like propylene glycol and other required additives.  An 
attempt will be done to enhance the transungual drug permeation of Miconazole nitrate 
using various permeation enhancers. 
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 2.2 Plan of work 
A.Pre formulation studies  
 
 Physicochemical parameters  
a) Solubility profile 
                 b) Melting point determination 
 Analytical method  
                                               a) Determination of ʎmax  
                                                   b) Development of standard curve of Miconazole nitrate  
 Determination of compatibility of drug with polymer  
a) By FTIR spectroscopy  
 
B.Formulation of  nail lacquer and optimization of permeation enhancer 
 
C.  Evaluation of lacquers  
 Non -volatile content  
 Drying rate & film formation  
 Smoothness to flow  
 Gloss  
 Viscosity 
 Adhesion 
 Percentage drug content determination 
 In vitro diffusion study  
 In vitro ungual permeation studies 
 Anti- microbiological studies  
 Stability studies as per ICH guidelines 
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3. REVIEW OF LITERATURE 
 
                    Tandel Amruta1 et al, 2012, in their research studied the Transungual 
permeation of the voriconazole nail lacquer against Trichophyton rubrum. The purpose of 
study was to determine amount of voriconazole permeating through the nail plate from the 
nail lacquer formulation containing permeation enhancer. The permeability studies were 
performed on avulsed human cadaver nail plates using modified Franz diffusion apparatus 
containing phosphate buffer saline in the acceptor chamber. The addition of thioglycolic 
acid, 5% improved the permeability of the drug by 0.7 as the enhancement factor25 
 
                     A N Merekar et al, 2012 formulated a medicated nail lacquer for preungual 
drug delivery. Enalapril Maleate was chosen as the model drug, and the formulations were 
prepared with and without polymer Eudargit RL 100 within the concentration range of 1% 
to 5% (w/v) in the polymeric system. Then, these lacquers were compared for glossiness, 
film formation, drying rate, smoothness of flow, and nonvolatile content. The in vitro 
studies were preformed on the artificial membrane in solvent A (phosphate buffer, pH 7.4; 
and methanol, AR grade, in the ratio of 4:1). The result obtained indicated that the nail 
lacquer formulation showed good release of the drug. Thus nail lacquers can be used as a 
successful tool for targeted drug delivery for hypertension.26 
                     Gupchup GV et al, 2010, has reviewed the Structural characteristics and 
permeability properties of the human nail. He reported that nail is primarily composed of a 
highly cross-linked keratin network that contains several disulfide linkages. Compounds 
containing sulfhydryl groups in conjunction with keratolytic agents can significantly 
enhance drug penetration. Such sulfhydryl compounds are thought to reduce the disulfide 
linkages in the nail keratin matrix.1  
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                  S. Hadzidedic et al, 2010, in their article, Characterization of antifungal nail 
lacquer formulations containing fluconazole, developed six formulations of nail lacquer 
containing 0.9% (w/v) fluconazole, Eudargit RS 100 and acetone. The formulations contain 
ingredients like di-butyl phthalate, polyethylene glycol 400 or propylene glycol as 
plasticizers in two different concentrations. we characterized the developed formulations 
with regard to the drying time, fineness of formed film, fluconazole assay and viscosity. 27 
               R.Shireesh Kumar et al, 2010, reported that Transungual delivery of 
ketoconazole from the nail lacquer for topical therapy of nail disease is limited by poor 
bioavailability of nail plate. They made various trials with permeation enhancers like 
cysteine, thioglycolic acid, urea, hydrogen peroxide and found an increase in permeability 
of applied ketoconazole drug.20 
                Ghannoum MA et al, 2010 determined the efficacy of different Terbinafine 
hydrochloride nail solutions (TNS) formulated with/without dodecyl-2-N,N-dimethyl 
amino propionate hydrochloride (DDAIP HCl). TNS containing 1%, 5% and 10% 
Terbinafine hydrochloride formulated with and without DDAIP HCl demonstrated high 
antifungal efficacy27 Venjnovic I et al, 2010 determined the amount of Terbinafine 
hydrochloride penetration through the human nail plates from the liquid formulations 
containing enhancers hydrophobins A-C in the concentration of 0.1% (w/v). The used 
reference solution contained 10% (w/v) of Terbinafine in 60% (v/v) ethanol/water without 
enhancer. All tested hydrophobins facilitated terbinafine permeation after 10 days of 
permeation experiment; however one of them achieved an outstanding enhancement factor 
of 13.05 compared to the reference.28  
             Sigurgeirsson B et al, 2010 determined the efficacy of Amorolfine nail lacquer for 
the prophylaxis of Onychomycosis for a period of over 3 years. During the study 
Amorolfine was found safe and well tolerated during the study, with no treatment-related 
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adverse events.29  
                Monti D, et al, 2010 evaluated the antimycotic activity of a new water-soluble 
nail lacquer containing Ciclopirox (CPX/sol.  Application of the Ciclopirox /sol nail 
lacquer allows rapid nail penetration of Ciclopirox, providing Ciclopirox levels sufficient 
to inhibit fungal growth for a prolonged period of time after application of lacquer dose.30 
               Sudaxshina M et al, 2010 reviewed the recent research into ungual drug delivery 
and also the drug delivery of nail lacquers through the nail and its penetration. Also 
reviewed the various factors affecting the drug uptake and penetration through the nail 
plate.31  
 
                 Togni G et al, 2010, investigated the in vitro antifungal activity and in vitro an 
in vivo nail permeation of 8% Ciclopirox nail lacquer (P-3051). P-3051 is based on 
hydroxypropyl chitosan as film forming agent. P-3051 and the reference showed the same 
protective activity in experimental infections with strains of dermatophytes isolated from 
clinical samples.32  
 
                Bohn M et al, 2010, determined the Dermatopharmacology of Ciclopirox nail 
lacquer topical solution 8% in the treatment of Onychomycosis. Ciclopirox has been 
formulated in a nail lacquer delivery system. After evaporation of volatile solvents in the 
lacquer, the concentration of ciclopirox in the remaining lacquer film reaches 
approximately 35%, providing a high concentration gradient for penetration into the nail.33 
             
                  Nadkar S et al, 2010, gave an OTC perspective of current trends of novel drug 
delivery systems. The global scenario and regulations in OTC category are introduced and 
the key potential delivery platforms and therapeutic categories in the OTC market are been 
highlighted.34  
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                   Roberts DT et al, 2010, gave the guidelines for treatment of Onychomycosis 
prepared for dermatologists on behalf of the British Association of Dermatologists. They 
present evidence-based guidance for treatment, with identification of the strength of 
evidence available at the time of preparation of the guidelines, and a brief overview of 
epidemiological aspects, diagnosis and investigation.35  
                       Andrea Mayumi Koroishi et al, 2010, Antifungal activity and nail 
permeation of nail lacquer containing piper regnellii (miq.) c. cd. var. pallescens (c. dc.) 
yunck (piperaceae) leave extracts and derivatives, For this study the antidermatophyte 
activity of the extracts and derivates from leaves of Piper regnellii was analyzed. Nail 
lacquer containing the chloroform fraction showed good penetration through the nail as 
determined by photoacoustic spectroscopy. From in vitro studies it was observed that nail 
lacquer concentrations above 20 mg/mL prevented the growth of fungi, but concentrations 
up to 2.5 inhibited the growth. The specie P. regnellii showed great antifungal activity 
against T. rubrum, and nail lacquer containing its chloroform fraction has great potential to 
treat onychomycosis caused by this microorganisms.36  
 
                    Alessandro et al, 2009, the pharmaceutical forms most widely investigated are 
1% ciclopirox olamine cream and 8% ciclopirox acid nail lacquer. It penetrates into the 
deep layers of the skin, mucosal membranes and nail keratin, reaching concentrations 
exceeding the minimal fungicidal concentrations for most medically important fungi. 
Emphasis in this review is given to a ciclopirox medicated nail lacquer having good affinity 
to keratin and nail permeation. It has been found to have superior efficacy and safety to 
another commercially available formulation in the treatment of onychomycosis.37  
                       B. V. Mitkari et al, 2007, Formulation and Evaluation of Topical Liposomal 
Gel for Fluconazole, In the present work statistical study for the formulation of liposomes 
for topical delivery of fluconazole using the factorial design approach was undertaken. 
Amount of phospholipid (PL 90H) and cholesterol (CH) were taken at three different levels 
and liposomes were prepared using film hydration technique. Liposomal dispersion and  
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gels were found to increase the skin permeation and deposition compared to control and 
marketed gel. Liposome dispersion and gel formulation were found to be stable for 60 
days.38 
            R. P. Patel et al, 2009, Drug delivery across human nail, Topical nail preparations 
like lacqures, enamel ,varnishes are the integral part of today’s beauty treatments. It 
protects the nail plate, but more importantly it enhances their beauty, imparting colour and 
luster. The basic nail varnish contains solvents, film forming agents, resins which enable 
the film adhere to nail plate and convey shining to the film, plasticizers give flexibility and 
durability to the film. Nail diseases like onychomycosis, nail psoriasis, yellow nail 
syndrome, paronychia and many more , being crushed successfully using medicated nail 
lacquers.3 
 
                 Tulli A et al, 1988, the treatment of onychomycosis with a new form of 
tioconazole, the difficulties encountered in the treatment of onychomycosis are primarily 
related to the necessity of prolonged systemic therapy. Many of these difficulties could, 
then, be avoided by the use of an effective local treatment. The present study compared the 
effectiveness and tolerability of two topical ungual preparations: a 28% solution of 
tioconazole and a 2% tincture of Miconazole. The therapeutic results and tolerability of 
both preparations were found to be satisfactory. The tioconazole preparation proved to be 
slightly more effective although the difference was not statistically significant.39  
 
                Scher RK et al, 1998, Once-weekly fluconazole (150, 300, or 450 mg) in the 
treatment of distal subungual onychomycosis of the toenail, Onychomycosis is a prevalent 
infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro 
against the most common pathogens of onychomycosis, penetrates into the nail bed, and is 
clinically effective in the treatment of a wide variety of superficial fungal infections.40  
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                          B.Bentley-philllps, 1982, The treatment of onychomycosis with 
miconazole tincture,Treatment of onychomy.cosis is usually unsatisfactory. A small 
clinical trial using a solution of miconazole (Daktarin; Janssen) in alcohol was undertaken 
to assess its potential in this difficult condition. Ten unselected patients completed the 32-
week trial and the results, irrespective of whether the infecting organism was fungal or 
monilial, are recorded. A much larger and controlled trial is essential before firm 
conclusions may be drawn, but the results, particularly in Candida infections, are 
encouraging.41 
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4. DRUG AND POLYMER PROFILE 
 
4.1 Miconazole Nitrate42, 43 
Table No.2:Properties of Miconazole nitrate 
Proprietary name Desenex, Monistat, Zeasorb-AF 
IUPAC Name (RS)-1-(2-(2,4-Dichlorobenzyloxy)-2-
(2,4dichlorophenyl)ethyl)-1H- imidazole 
 
 
 
Molecular formula 
 
 
C18 H14 Cl4 N2 O 
Molecular weight 416.127 g/mol 
CAS No 22961–47–8 
Melting Point 159-163 °C 
 
 
Structure 
 
Figure 4: Structure of Miconazole nitrate 
 
Description                           :  The drug was found to be white crystalline powder with   
                                                     slight characteristic odour 
Solubility of Miconazole      : Soluble in methanol, Ethanol, Acetone 
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Mechanism of action 
 
                      Miconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme 
necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of 
the fungal cell membrane, inhibition of its synthesis results in increased cellular 
permeability causing leakage of cellular contents. 
 
                       Miconazole may also inhibit endogenous respiration, interact with 
membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit 
purine uptake, and impair triglyceride and/or phospholipid biosynthesis. 
 
Pharmacokinetics 
                      Oral absorption of Miconazole (Nitrate) is found to be 20%. Volume of 
distribution is found to be 20 l/kg and plasma protein binding is 92 %. And metabolism 
is reported Hepatic. Renal Excretion accounts for 20 % and plasma half- life is 24.1 hr. 
 
Dose    
Adult Dosage            : 2% for Ophthalmic and topical, 250.000 mg for PO 
Paedriatic Dosage       : 0.330 to 0.500 mg/kg as IV Infusion, 2.000 % for topical 
 
Drug class                  : Anti -fungal  
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        4.2 POLYMER PROFILE 
4.2.1. Nitrocellulose 44, 45 
Table No.3: Properties of Nitrocellulose 
Synonyms Cellulose nitrate, flash paper, flash cotton, flash string, 
guncotton, Celex,Celloidin, Cellulose Tetranitrate, Kodak LR 
115, Paralodion, Pyralin, Proxylin and Xyloidin 
Empirical formula    (C6H8(NO2)2O5)n 
Molecular Mass Variable 
CAS Number 9004-70-0 
Description Yellowish white cotton-like filament 
Melting point 160-170⁰C(ignites) 
Flash point 4.4⁰C 
Solubility Good solubility in alcohol-type solvents,water-30 or 35% 
Nitrogen Content 10.6-11.3% 
Viscosity Value 350 - 450 mPa.s 
Relative Density 0.8097g/cm3 
 
Structure 
 
Figure 5: Structure of Nitrocellulose 
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Production  
                  4-5gm of cellulose base (cotton) is added to concentrated sulfuric acid and 
70% nitric acid (50:25ml) cooled to 5-10 °C to give cellulose trinitrate. Then cotton was 
removed and washed in cold water and solution of remove all acid residues. It was then 
slowly dried at a temperature. The process uses nitric acid to convert cellulose into 
cellulose nitrate and water. 
 
3HNO3+ C6H10O5 → C6H7(NO2)3O5 + 3H2O 
Hazards identification 
                 
                         Label precautionary statements: flammable (usa), highly Flammable 
(eu). Keep away from sources of ignition—no Smoking. Take precautionary measures 
against static discharges. Wear suitable gloves and eye/face protection. 
 
Incompatibilities 
 
      Strong acids, strong bases, cellulose and its derivatives may react vigorously with 
calcium oxide, bleaching powder, perchlorates, perchloric acid, sodium chlorate, 
flourine, nitric acid and sodium nitrate. 
 
Uses 
                Propellant or low-order explosive, film base in photograph, X-ray films and 
motion picture films. 
 
Storage     
                 Storing it wet or in oil, avoid direct sunlight. 
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4.2.2 Ethyl Cellulose46 
Table No.4: Properties of Ethyl cellulose 
 
 
 
 
 
 
 
 
 
 
 
 
 
Solubility    
    Insoluble in water & glycerin, but soluble in varying degree in certain organic 
solvents, depending upon the ethoxyl  content. 
 
Functional Category: 
                                       Coating agent 
                                       Flavoring fixatives 
                                       Tablet binder & filler  
                                       Viscosity-increasing agent. 
Applications in Pharmaceutical Formulation or Technology 
                                 Ethyl cellulose is widely used in oral and topical pharmaceutical 
formulations. Ethyl cellulose coatings are used to modify the release of a drug, to mask 
an unpleasant taste, or to improve the stability of a formulation. Ethyl cellulose, 
dissolved in an organic solvent or solvent mixture, can be used on its own to produce  
Nonproprietary Names               BP: Ethyl cellulose, PhEur: Ethylcellulosum, 
USPNF:Ethylcellulose 
Synonyms     Aquacoat ECD; Aqualon; Ethocel; Surelease. 
Molecular formula (C12H23O5)n 
CAS Number                                9004-57-3 
Description   Ethyl cellulose is a tasteless, free-flowing, white to 
light tan- coloured powder 
Density (Bulk)                                    0.4 g/cm3 
Specific Gravity                                 1.12-1.15 g/cm3 
Melting Point                                   158-162oC. 
Moisture content                                ethyl cellulose absorbs very little water from humid 
air or during immersion, and that small amount 
evaporates readily 
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water-insoluble films. Higher-viscosity ethyl cellulose grades tend to produce stronger 
and more durable films.. In topical formulations, ethyl cellulose is used as a thickening 
agent in creams, lotions, or gels, provided an appropriate solvent is used. 
Structure 
 
Figure 6: Structure of Ethyl cellulose 
Stability and Storage Conditions 
                               Ethyl cellulose is a stable, slightly hygroscopic material. It is 
chemically resistant to alkalis, both dilute and concentrated, and to salt solutions, 
although it is more sensitive to acidic materials than are cellulose esters. Ethyl cellulose 
should be stored at a temperature not exceeding 32°C in a dry area from all sources of 
heat. It should not be stored next to peroxides or other oxidizing agents. 
4.2.3. 2- Hydroxypropyl -β-Cyclodextrin 46 
Structure 
 
 
Figure 7: Structure of β-cyclodextrin (7 glucose units) 
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Rƍ, RƎ = H for ‘natural’ α-, ȕ- and Ȗ-cyclodextrins 
Rƍ, RƎ = CH3 for methyl cyclodextrins 
Rƍ, RƎ = CHOHCH3 for 2-hydroxyethyl cyclodextrins 
Rƍ, RƎ = CH2CHOHCH3 for 2-hydroxypropyl cyclodextrins 
 
Table No.5: Properties of 2- Hydroxypropyl -β-Cyclodextrin 
 
Synonyms Beta-cyclodextrin, ßCD, BCD, ß-Schardinger dextrin, 
cyclodextrin B. 
Definition A non-reducing cyclic saccharide consisting of seven 
alpha-1,4-linked D-glucopyranosyl units 
Manufactured by the action of cyclodextrin 
transglycolase on hydrolysed starch followed by 
purification of the ß-cyclodextrin; purification is by 
preparation of a ß-cyclodextrin/solvent     inclusion 
compound followed by steam-stripping of the solvent 
before final purification. 
Chemical names     Cycloheptaamylose 
C.A.S. number         7585-39-9 
Chemical             
formula 
(C6H10O5)7 
Formula weight        1135.00 
Description Virtually odourless, slightly sweet tasting white or 
almost white crystalline   solid 
Solubility Β-cyclodextrin: soluble 1 in 200 parts of propylene 
glycol, 1 in 50 of water at 20°C, 1 in 20 at 50°C; 
practically insoluble in acetone, ethanol (95%),                               
and methylene chloride. 
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Functional Uses   : Encapsulation agent for food additives, flavoring and vitamins 
                                 
                                 
                                 To improve the organoleptic properties of drugs by masking    
                                  bitter   taste and nauseous taste. 
4.2.4. Salicylic Acid46 
Structure: 
 
 
Figure 8: Structure of salicylic acid 
Table No.6: properties of Salicylic Acid 
 
 
Non-Proprietary 
Name 
Acidum Salicylicum U. S. P 
  
Synonym      2 hydroxy benzoic acid 
Empirical formula         C6H4(OH)COOH 
Molecular Mass              138.12 g mol−1 
 
CAS Number                  69-72-7 
Solubility                Poorly soluble in water (2 g/L at 20 °C), freely soluble in 
alcohol 
Density                   1.443 g/cm3 
Melting Point        159.0 °C, 432 K, 318 ° 
Boiling Point          211 °C, 484 K, 412 °F (20 mmHg) 
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4.2.5. Propylene Glycol46 
Structure 
 
Figure 9: Structure of propylene glycol
Table No.7: Properties of Propylene Glycol 
Non-proprietary name        BP :Propylene  glycol,  JP:  Propylene  glycol,  
 PhEur:  Propylene  glycol, 
Synonyms   α-propylene glycol, 1,2-propanediol, 1,2-
Dihydroxypropane, methyl ethyl glycol(MEG), 
methylethylene glycol, PG, Sirlene, Dowfrost. 
IUPAC name                      propane-1,2-diol 
Molecular formula             C3H8O2 
Molar mass                         76.09 g/mol 
CAS number                         57-55-6 
Description   Colorless, odorless, clear, viscous liquid with a 
faintly sweet taste. 
Density   1.036g/cm³ 
Melting point                      −59 °C (−74 °F) 
Boiling point                        188.2 °C (370.8 °F) 
Solubility Soluble in water, ether, ethanol, chloroform 
Specific Gravity                    1.036 (Water = 1) 
Water/Oil Dist. Coeff.            The product is more soluble in water; log(oil/water) = 
-0.9 
Viscosity (dynamic)               58.1-mPa s (58.1 CP) at 20°C. 
Storage Hygroscopic. Keep container tightly closed. Keep 
container in a Cool, well-ventilated area. Do not store 
above 23°C (73.4°F). 
 
Uses   
Propylene glycol has been used as a solvent, extractant, and preservative in a variety of 
parenteral and nonparenteral pharmaceutical formulations. 
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5. MATERIALS AND METHODS 
 
5.1 .LIST OF MATERIALS USED 
 
Table No.8: List of materials used 
 
Sl.no Materials used* Sources 
1 Miconazole nitrate Yarrow chemicals,  Mumbai 
2 HP- β- CD Yarrow chemicals,  Mumbai 
3 Ethyl cellulose Kemphasol, Popatwadi, Mumbai 
4 Nitro cellulose Kemphasol, Popatwadi, Mumbai 
5 Propylene glycol Laboratory grade, Otto kemi, Mumbai 
6 Salicylic acid Laboratory grade, Nice chemicals Pvt. Ltd 
Cochin 
7 Ethyl alcohol Laboratory grade,Jiangsu Huaxi 
InternationalTrade Co.Ltd,China 
8 Sodium hydroxide Laboratory grade, Nice chemicals Pvt. Ltd 
Cochin 
9 Potassium dihydrogen 
phosphate 
Laboratory grade, Nice chemicals Pvt. Ltd 
Cochin 
 
 
 
*All chemicals and solvents used were of Analytical grade. 
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5.2. LIST OF EQUIPMENT USED: 
 
Table No.9: List of equipments used 
 
 
Sl.no: Equipments Manufacturers 
1 Electronic weighing balance Shimadzu Corporation, 
Japan 
2 FT-IR Perkin Elmor, USA 
3 Double beam UV spectrometer Shimadzu Corporation, 
Japan 
4 Magnetic stirrer Remi Electrotechnic Ltd, 
Vasai India 
5 Desiccator Technico, Delhi 
6 Franz diffusion cell Murthys, Hyderbad 
7 Hot air oven Rotex instruments, B&C 
industries, Kerala 
8 Screw gauge Technico, Delhi 
9 Tensile strength apparatus Dept. of Pharmaceutics, 
APSC 
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5.3. PREFORMULATION STUDIES 
 
5.3.1. Identification Drug 
 
A) Solubility study47 
Saturated solubility of Miconazole nitrate was prepared using 10 ml of 
distilled water/ ethanol/ acetone in 25 ml volumetric flasks in triplicate. Precaution was 
taken so that the drug remains in medium in excess. Then by using mechanical shaker, 
the flasks were shaken for 48 hours. The sampling was done on 24th & 48th hour. The 
sample withdrawn (1 ml after filtration) was diluted with appropriate medium and 
analyzed by using UV spectrophotometer at 223 nm. 
 
B) Melting point determination47 
 
                    Melting point of drug was determined by taking a small quantity of drug in 
a capillary tube sealed at one end and was placed in Thiel’s melting point apparatus and 
temperature range at which the drug melted was noted. Average of triplicate readings 
was noted. 
 
C) Determination of λ max 
 
100 mg of pure Miconazole nitrate was taken in a volumetric flask and 
dissolved in a little of phosphate buffer pH of 7.4 and volume made up to100ml. 1ml of 
the above solution was taken and further diluted to 100ml. The above solution scanned 
for maximum absorbance in double beam UV-Visible spectrophotometer in between the 
range of 400-200 nm against phosphate buffer pH 7.4 as the blank. Triplicate readings 
were taken and average was calculated. 
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5.3.2. ANALYTICAL METHODS 
 
A) Preparation of Phosphate buffer solution47 
 
Preparation of 0.2M Sodium hydroxide solution 
 
8gm of sodium hydroxide was dissolved in sufficient quantity of distilled 
water in a 1000ml volumetric flask and volume was made up to 1000ml with distilled 
water. 
 
Preparation of 0.2M potassium dihydrogen ortho phosphate solution 
 
27.218gm of potassium dihydrogen orthophosphate was dissolved in 
sufficient quantity of distilled water in a 1000ml volumetric flask and volume was made 
up to 1000ml with distilled water. 
 
Preparation of phosphate buffer solution of pH 7.4 
 
50ml of potassium dihydrogen ortho phosphate solution was taken in a 
200ml volumetric flask and 39.1ml of 0.2M sodium hydroxide solution was added and 
made up to 200ml with distilled water. 
 
B) Preparation of standard stock solution & Calibration curve of Miconazole 
nitrate 
 
100mg of Miconazole nitrate pure drug was accurately weighed and 
transferred into a 100ml volumetric flask. Then the volume was made up to 100ml with 
PBS of pH 7.4, to obtain standard stock solution of Miconazole nitrate, having 
concentration 1000mcg/ml. 
                       From the above solution aliquots of 2ml, 4ml, 6ml, 8ml, 10ml was 
pipetted out into another 100ml volumetric flask and made up to 100ml with PSB of pH  
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7.4 to obtain a concentration range of 20µg/ml, 40µg/ml, 60 µg/ml, 80 µg/ml, and 
100µg/ml solution. This solution was analyzed at 223nm by using UV- Visible 
spectrophotometer. A graph of concentration Vs. absorbance was plotted. Drug content 
estimation and diffusion studies were based on this calibration curve. 
 
5 .3.3. Determination of drug- polymer compatibility 
 
FT-IR spectral analysis of pure drug and polymer were carried out 
individually and as mixtures. The compatibility between Miconazole nitrate, 
nitrocellulose, 2-HP- β- CD, propylene glycol and prepared formulation were carried 
out in the ratio 1:1. The samples were placed FT-IR window after mixing and triturating 
with potassium bromide. 
 
 
Table No. 10:  Drug- polymer compatibility study 
 
 
Composition Ratio 
250C±2 400C±2 
/600CRH /750C RH   
    
Miconazolenitrate 100mg 6 Months 1 Month 
    
Nitrocellulose 100mg 6 Months 1 Month 
    
HP- β- CD 100mg 6 Months 1 Month 
    
Propylene glycol 100mg 6 Months 1 Month 
    
Miconazole+ 
nitrocellulose 1:1 6 Months 1 Month 
    
Miconazole + HP- 
β- CD 1:1 6 Months 1 Month 
    
Final Formulation 
NA 6 Months 1 Month 
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         5.4. FORMULATION STUDIES 
 
5.4.1. Development of nail lacquer of Miconazole nitrate 
 
A) Preparation of Nitrocellulose48 
 
                      About 5gms of cellulose base (cotton) is added to 50ml concentrated   
sulfuric acid and 25ml 70% nitric acid mixture and cooled to 5-10 °C to give cellulose 
nitrate. Then cotton was removed and washed in cold water and with NaHCO3 solution 
to remove all acid residues. It was then slowly dried at room temperature. 
 
 
B) Optimization of Nitrocellulose film former 
 
 
Table No.11: Optimization of nitrocellulose film former 
 
Formulation 
              
Nitrocellulose 
      
Plasticizers(%w/v) Ethanol(ml) 
code (%w/v) 
         
PG Glycerin 10 
NF1 2 10 …. 10 
NF2 4 10 …. 10 
NF3 6 10 …. 10 
NF4 8 10 …. 10 
NF5 2 …. 10 10 
NF6 4 …. 10 10 
NF7 6 …. 10 10 
NF8 8 …. 10 10 
 
 
                     Four different concentrations of nitrocellulose, 2%, 4%, 6%, 8%, were 
prepared using two different plasticizers, Propylene glycol and Glycerine at 10 % 
concentration as per Table No.11. The optimum concentration for film formation was 
determined by evaluating the thickness, tensile strength, folding endurance and water 
resistance. 
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C) Evaluations of nitrocellulose film 
a) Film thickness 49,50,51 
                      The thickness of the film was measured by using screw gauge with a least 
count of 0.01 mm at different spots of the films. The thickness was measured at five 
different spots of the film and average was taken. 
b) Folding Endurance49 
                              Folding endurance of the films was determined by repeatedly folding 
a small strip of the film (approximately 2x2 cm) at the same place till it broke. The 
number of times film could be folded at the same place, without breaking gives the value 
of folding endurance. 
c) Tensile Strength 50 
                          The instrument used to measure the tensile strength was designed in 
pharmaceutics laboratory especially for this project work. The instrument is a 
modification of chemical balance used in the normal laboratory as shown in Figure 
10. One pan of the balance was replaced with one metallic plate having a hook for 
attaching the film. The equilibrium of the balance was adjusted by adding weight to 
the right pan of balance. The instrument was modified in such a way that the patch 
can be fixed up between two hooks of horizontal beams to hold the test film. A film 
of 2.5cm length was attached to one side hook of the balance and the other side hook 
was attached to plate fixed up to the pan as shown in the Figure 10.   
            
             Tensile Strength (T) 
                                                 T= Mg/ Bt Dynes/cm2 
     T= force at break/ initial cross-sectional area of sample.   
              M = mass in grams 
     g = acceleration due to gravity 9.8m/sec² 
     B = breadth of the specimen in cm 
      t = thickness of sample in cm. 
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Figure 10: Tensile strength apparatus 
d) Water resistance51 
                             This is the measure of the resistance towards water permeability of 
the film. This was done by applying a continuous film on a surface and immersing it in 
water. The weight before and after immersion was noted and increase in weight was 
calculated. Higher the increase in weight lowers the water resistance. 
 
   5.4.2 Formulation of nail lacquer 
 
The formulation trials were done as per formula given in Table No: 12. 
The mixture of Miconazole nitrate and Nitrocellulose was dissolved in Ethyl alcohol in 
the required quantity using a magnetic stirrer at a constant speed. To above clear 
solution required quantity of 2-HP- β- CD , Salicylic acid, and propylene glycol were 
mixed thoroughly and made up to the volume to 100ml. The prepared nail lacquer was 
transferred to a narrow mouthed, plastic screw capped glass bottle. 
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Figure 11: Schematic representation of preparation of nail lacquer 
 
Table No.12: Formulation of Nail Lacquer 
 
 
Ingredients 
(%)   F0 F1 F2 F3 F4 F5 F6 F7 F8 F9 
 
F10 
 
F11 
Miconazole 
nitrate 2 2 2 2 2 2 2 2 2 2 2 2 
Nitrocellulo
se 
6 6 6 6 6 6 6 6 6 6 6 6 
Salicylic 
acid  5 10 15 20 15 15 15 15 15 15 15 
2-H- β-CD … … … … … 5 7.5 10 10 10 10 10 
Ethyl  
cellulose 
… … … … … … … … 0.25 0.50 0.75 1.00 
Propylene 
 Glycol 
10 10 10 10 10 10 10 10 10 10 10 10 
Ethanol  
 qs 100 100 100 100 100 100 100 100 100 100 100 100 
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   5.5 EVALUATION OF NAIL LACQUER3, 20, 21, 22 
 
A) Nonvolatile content 
 
           10 ml of sample was taken in a petri dish and initial weights were  recorded. 
The dish was placed in the oven at 1050C for 1hr, the petri dish was removed, cooled 
and weighed. The difference in weights was recorded. Average of triplicate readings 
was noted. 
 
B) Drying time 
         A film of sample was applied on a petri dish with the help of a brush. The time 
to form a dry-to- touch film was noted with the help of stop watch. 
 
C) Smoothness to flow 
          The sample was poured from a height of 1.5 inches into a glass plate and 
spread on a glass plate and made to rise vertically and visually observed for 
smoothness of film. 
D) Gloss 
         Sample of nail lacquer was applied over the nail and gloss was visually seen, 
compared with marketed cosmetic nail lacquer. 
E) Viscosity  
                 Viscosity was determined using Brookfield Viscometer, model LVF at room   
         temperature using spindle no. 3 at 20 rpm.  
F) Adhesion   
       There are no quantitative evaluation tools available to assess the medicinal nail 
lacquer at this time. Hence an equipment designed in the Pharmaceutics Lab has been 
used to determine the adhesive property of nail lacquer. The instrument is a 
modification of chemical balance used in the normal laboratory as shown in Fig.no: 
10. One pan of the balance was replaced with two stainless steel plates. In between 
the plates a film of 4 cm2 was prepared and adhered. The equilibrium of the balance 
was adjusted by adding a weight to the right pan of balance. The force required to pull 
away the plates is recorded and compared with a commercial cosmetic nail lacquer 
sample. 
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Force of Adhesion =   Mass x Acceleration due to gravity  
                               = Kilogram. meter/ second2 
                                              
= Newtons.meter/seconds2 
Adhesive Strength =     Force of Adhesion   (N) 
                                      Surface area (m2) 
 
G) Drug content estimation49 
 
             Nail lacquer equivalent to 200mg was dissolved in 50 ml phosphate buffer 
solution of pH 7.4. Then the solution was ultrasonicated for 15 mints. The resulting 
solution was filtered, made up to 100 ml with phosphate buffer solution of pH 7.4. 
From the above solution take 10ml and made up to 100ml with PBS of pH 7.4. Then the 
diluted solution was estimated spectrophotometrically at wavelength of 223 nm and 
determined the drug content. 
 
H) Diffusion studies across artificial membrane 3, 20, 21 
           Diffusion studies were performed by Franz diffusion cell using artificial 
membrane (cellophane) of 0.8µm. The membrane was soaked for 24hrs in solvent 
system and the receptor compartment was filled with solvent.  
 
         Nail lacquer equivalent to 200mg was applied evenly on the surface of the 
membrane. 
          The prepared membrane was mounted on the cell carefully to avoid entrapment 
of air bubbles under the membrane. The whole assembly was maintained at 37°C, and 
the speed of stirring was kept constant for 20hrs. The 5ml aliquot of drug sample was 
taken at time intervals of 2hr, 4hr, 6hr, 8hr, 10hr, 12hr, 16hr and 20hrs and was 
replaced by the fresh solvent. Samples were analyzed by double-beam UV 
spectrophotometer as per method mentioned in drug content estimation. Each 
experiment was repeated thrice. 
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I) In vitro ungual permeation studies49 
          Hooves from freshly slaughtered cattle, free of adhering connective and 
cartilaginous tissue, were soaked in distilled water for 24hrs. Membranes of about 1mm 
thickness were cut from the distal part of hooves. In vitro permeation studies were 
carried out by using Franz diffusion cell, the hoof membrane was placed carefully on 
the cell. Then the nail lacquer equivalent to 200mg was applied evenly on the surface of 
the nail membrane. The receptor compartment was filled with solvent phosphate buffer 
solution of pH 7.4, and the whole assembly was maintained at 37°C with constant 
stirring for 48hrs. The 5ml aliquot of drug sample was taken after a time intervals of 2, 
4, 6, 8, 10, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48hrs and was replaced by the fresh 
solvent. The drug analysis was done by using double-beam UV spectrophotometer at 
223nm. 
 
J) Determination of antimicrobial activity 49 
               Candida albicans were employed for testing antifungal activity using the 
cup-plate method. The culture was maintained on sabouraud’s agar slants. 20 ml of 
melted sabouraud’s agar medium was inoculated with 72 hrs. old 0.2 ml suspension 
of Candida albicans in the Petri dish and allowed to set by keeping undisturbed for 
15 mints.  
   The cups (10mm diameter) were punched in the Petri dish and filled 
with 0.05 ml of a solution of the sample. The plates were kept for diffusion at 400C for 
1hr, and followed by incubation at 300 C for 48 hrs. After the completion of incubation 
period the zone of inhibition in millimeter were measured. Along with the test solution 
in each petri dish one cup was filled up with solvent, which act as control. The zone of 
inhibition was recorded and compared with control. 
 
K) Stability study 
                               Stability studies of nail lacquers were carried out as per ICH 
guidelines. Samples were stored at temperature of 25±2 0C/60 ± 5% RH for 6months 
and 40 ± 2oC/75 ± 5% RH for 1 month. Then the samples were analyzed for non -
volatile content, drying time, gloss, smoothness of flow, drug content and diffusion 
across artificial membrane. 
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6. RESULTS AND DISCUSSIONS 
 
6.1. Results for Analytical study      
6.1.1 Scanning of drug 
Pure Miconazole nitrate  sample was scanned using phosphate buffer 
solution (PBS) of pH 7.4 between 200nm to 400nm using UV visible 
spectrophotometer. The highest peak of Miconazole nitrate    was obtained at 223nm 
(Figure 12) and thus the λmax of Miconazole nitrate  was fixed at 223nm and was used 
further spectrophotometric evaluations during the investigation. 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: UV spectrum of Miconazole nitrate  in phosphate buffer solution of 
pH 7.4 
       
         6.1.2 Standard curve for Miconazole nitrate in phosphate buffer of pH 7.4 
                   Standard solutions of Miconazole nitrate in different concentrations 
(Table No.13) were prepared using PBS pH 7.4 and their absorption was measured at 
223nm. Drug concentration Vs. absorbance was plotted in Figure 13. 
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Table No.13: Standard curve data for Miconazole nitrate  in phosphate 
buffer of pH 7.4 
 
 
 
 
 
 
 
 
Figure 13: Calibration curve of Miconazole nitrate in phosphate buffer solution 
pH 7.4 
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Concentrations 
µg/ml 
Absorbance at 
223nm 
0 0 
20  0.124 
40 0.245 
60 0.364 
80 0.487 
100 0.609 
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6.2 PREFORMULATION STUDIES 
 
6.2.1 Solubility studies of Miconazole nitrate 
 
The result of solubility studies of pure Miconazole nitrate are given below: 
 
Table No.14: Solubility studies of Miconazole nitrate 
Solvents 
Solubility 
(mg/ml) 
Ethanol 0.78 
Water 0.03 
Acetone 0.36 
 
From the data, solubility profile of Miconazole nitrate was insoluble in water, soluble 
in ethanol and acetone. 
6.2.2 Melting point determination 
 
The melting point was found to be 1610C ± 0.577 and as per the IP 
2007 melting point of Miconazole nitrate was within the range of 159-163 °C. 
 
6.3 Drug excipient compatibility study 
                       All the reference IR peaks of the pure drug Miconazole nitrate were also 
present in  the  spectra  of  mixture  of  drug-  polymer  and  drug-permeation  
enhancer-excipients  as mentioned in the above Table No 10. 
So FTIR study showed that there is no interaction between drug and permeation 
enhancer. So the drug and permeation enhancer are compatible. The IR spectrums 
were given in the Figures 14 to 20. 
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Figure 14: IR spectra of Miconazole nitrate 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: IR spectra of Nitrocellulose 
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Figure 16:IR spectra of Ethyl cellulose 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: IR spectra of β- hydroxy Propyl Cellulose 
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Figure 18: IR spectra of Miconazole nitrate and Nitrocellulose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: IR spectra of Miconazole nitrate and β- hydroxy Propyl Cellulose 
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Figure 20: IR spectra of Miconazole nitrate Optimized Nail Lacquer 
Formulation (F11) 
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Table No.15:  FTIR Compatibility study interpretation 
 
FTIR spectra of pure Miconazole 
nitrate  
 
Miconazole nitrate Optimized Nail 
Lacquer Formulation (F11) 
 
Wave 
number 
(cm1)  
Functional group  
Functional 
group  
Wave number 
(cm1)  
 
3281.15  
 
Imidazole CN 
stretch  
Imidazole CN 
stretch  3178.76  
 
3254.78  
 
Aromatic CH 
stretch  
Aromatic CH 
stretch  3106.41  
 
2972.93  
 
Aliphatic CH2 
stretch  
Aliphatic CH2 
stretch  2958.94  
 
2885.64  
 
Aliphatic CH 
stretch  
Aliphatic CH 
stretch  2900.09  
 
1448.73  
 
CH2 bending  CH2 bending  1473.95  
 
1416.04  
 
CH bending 
(aliphatic)  
CH bending        
(aliphatic) 1410.93  
 
1329.03  
 
CN stretch  CN stretch 1329.72 
 
1083.82  
 
CC stretch  CC stretch 1087.46 
          C=C 
aromatic 1587.04  
         C=C 
aromatic 1546.70  
 CH bending 
(aromatic) 711.62 
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                After spectral comparison it was confirmed that no incompatibility reaction 
took place between drug and excipients, as all major characteristic IR peaks of 
Miconazole nitrate are present in the physical mixture with individual excipients and 
also in the final optimized formulation, F11. All the excipient peaks were found to be 
intact indicating good compatibility.  
 
6.4 Formulation development of Nail Lacquer 
 
The objective of the present study was to provide a formulation for 
inhibiting fungal growth on or underneath toe nails or finger nails so that the 
appearance of the nails are improved. Formulation includes a film former 
nitrocellulose, permeation enhancer such as 2-H- β-CD, keratolytic agent like salicylic 
acid and an antifungal agent (Miconazole nitrate) and ethanol as solvent. Formulation 
is prepared by simple mixing method. 
Miconazole nitrate nail lacquers were evaluated on the basis of their 
film formation, smoothness of flow, drying time, gloss, nonvolatile content, viscosity 
and water resistance properties. 
 
6.4.1 Optimization of nitrocellulose film former 
 
Different concentrations of film forming polymers were used for film 
formation and then used for optimization of film. Different concentrations were tried 
between 2-8%. From the result, it was observed that by increasing the concentration of 
polymer up to 6%, thickness and strength of film was improved. When increasing 
concentration more than 6%, sticky films were formed. Thus, 6% concentration of 
polymer was used for further optimization of plasticizer. Plasticizer tried were 
Glycerin and Propylene glycol in 10% concentration each. Glycerin showed more 
sticky film which was unable to detach from surface. Propylene glycol showed good 
film forming property with good flexibility. Thus, 6% nitrocellulose and 10% 
propylene glycol, due to its excellent film forming nature was selected for further 
optimization studies. 
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A) Thickness (µm) 
 
Uniform thickness indicates the uniformity of the formulations thereby 
suitability of the executed procedure. Thickness of all the films measured by using a 
micrometer screw gauge. Results showed that thickness of all formulations varied 
from 55 to 59 µm.  
The observed values were enlisted in the Table No.16. Data for film thickness 
was matching within the desired range of thickness identified through review of 
literatures for films. 
 
B) Folding endurance  
Folding endurance indicates the flexibility of the polymer film. In order 
to evaluate the flexibility, the prepared films were subjected to folding endurance 
studies. The number of folds a film can sustain without break will dictate its folding 
endurance. The values obtained were above 125 in all of the developed films and are 
listed in Table No.16 and it was in the range of 126-178 for all the developed films. 
Irrespective of polymer concentration used, all the films showed good folding 
endurance, revealed that the prepared films were having the capacity to withstand the 
mechanical pressure along with good flexibility. The folding endurance is an 
important evaluation, which ensures the flexibility of the developed films. Higher the 
folding endurance values better will be the flexibility of the films. 6% film (NF3) 
showed good folding endurance, thereby ensuring good flexibility. 
 
           C) Tensile strength (Kg/cm2) 
                          Tensile strength indicates the flexibility / elasticity of the film and 
its capacity to withstand a mechanical pressure. The tensile strength values depend 
on the percentage of the polymer solutions and polymer: plasticizer ratio. Tensile 
strength was measured by using an instrument designed and developed exclusively 
for the project. Since all the formulations have different proportions of polymers, 
from the data mentioned in Table No.16 it was clear that 6 % concentration of 
nitrocellulose (NF3) showed higher tensile strength and the lowest average tensile 
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strength value was recorded for 8 % film. 
 
Table No.16: Optimization of nitrocellulose film former 
 
Nitrocellulose 
Concentration 
(%w/v) 
 
1 
 
2 
 
3 
 
4 
Thickness (µm) 58±0.02 59±0.02 55±0.04 58±0.03 
Folding 
endurance 
155 126 178 177 
Tensile 
strength 
(Kg/cm2) 
2.56±0.01 2.58±0.01 2.60±0.04 2.55±0.02 
 
B) Water resistance 
This is the measure of the resistance towards water permeability of the 
films. This was done by applying a continuous film on a surface and immersing it in 
water. The weight before and after immersion was noted and increase in weight was 
calculated. Higher the increase in weight lowers the water resistance. Here 
Nitrocellulose Film of 6% (NF3) has comparatively low weight and has the better 
water resistance. The datas were mentioned in Table No.17. 
TableNo.17: Water (W) resistance of nail lacquers 
Formulation 
code 
W1(g) W2(g) 
NF1 6.85 6.92 
NF2 6.83 6.95 
NF3 6.88 6.90 
NF4 6.92 7.14 
NF5 6.81 6.90 
NF6 6.84 6.91 
NF7 6.89 6.94 
NF8 6.90 7.04 
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                             Based on above studies it was decided that, NF3 formulation has the 
ideal characteristics required for a nail lacquer and hence 6% w/v of nitrocellulose and 
10%w/v of Propylene glycol was concluded to be the optimum concentrations.   
 
6.5. Evaluation of nail lacquer 
 
All formulations showed desired film formation, smoothness of flow was good. 
Desired amount of nonvolatile matter (31 - 41%) was seen with complete evaporation 
of volatile matter leaving a thin film; the results were plotted in Table No.18. Drying 
time was found within 52 -127 sec. Except for F2, where it showed 127 sec, all 
formulations showed rapid drying rate. ie less than 60 seconds. The datas were 
mentioned in Table No.19.   
 
A) Nonvolatile content 
 
The non- volatile content of all formulations has been reported in the Table No.18, 
given below 
Table No.18: Nonvolatile content of nail lacquers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
code 
Non-
volatile  
content 
(%) 
Formulation 
code 
Non-volatile  
content(%) 
F0 33±0.38 F6 37±0.81 
F1 33±0.38 F7 35±0.70 
F2 41±0.81 F8 31±0.40 
F3 39±0.40 F9 34±0.41 
F4 37±0.81 F10 33±1.22 
F5 35±0.71 F11 36±0.81 
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B) Drying time 
 
Table No.19: Drying time of nail lacquers 
Formulation Drying time Formulation Drying time 
Code (sec) code (sec) 
    
F0 50 F6 56 
    
F1 52 F7 59 
    
F2 127 F8 55 
    
F3 52 F9 59 
    
F4 58 F10 58 
    
F5 59 F11 56 
 
 
C) Smoothness to flow and Gloss:  
                                          Both these parameters was found to be satisfactory as 
can be observed from Fig. The nail lacquer poured onto the glass plate was found 
to spread and result in a uniform smooth film . The gloss of the applied lacquer 
was comparable with marketed cosmetic sample proving the cosmetic 
acceptance.  
         Figure 21: Smoothness to flow and Gloss of nail lacquer 
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D) Viscosity     
                                The viscosity of the sample ranged from 100 to 220 
centipoise and it was observed that between 140 to 160 centipoise the product 
was clear and glossy. More over this viscosity range provided good adherence 
and flow property. Viscosity outside this range produces clouding and decreases 
gloss which will not be cosmetically acceptable.   
Table No. 20: Viscosity of nail lacquers 
Formulation 
code 
Viscosity Formulation Viscosity 
 Code 
F1 100 F7 200 
 
111 
 140 
F2 F8  
 
 
 
 
F3 122 F9 142 
 
133 
 
 
F4 F10 146 
 
184 
  
F5 F11 152 
 
198 
                                                                                                                             
 
F6 
  
    
 
E) Adhesive strength 
                      The adhesive strength of the optimum batch was found to be 
comparable with marketed sample and hence can be expected to possess 
adequate adhesive strength on applied nail surface. 
Table No. 21: Adhesive strength of nail lacquers 
Formulation 
Code 
Force of Adhesion (N) Adhesive strength (N/m2) 
F11 0.5 12.5 
MARKET 
SAMPLE 
0.6 15 
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F) Percentage drug content determination 
 
Percentage drug content for all the lacquers were found to be 
satisfactory and in between 86.25-99.01% which is reported in Table No.22. Highest 
% of drug content was found to be 99.01% (F11) and the lowest % of drug content 
was 86.25% (F3). Drug content more than 90% in the formulation shows the high 
amount of drug present in the formulation, ensuring that the methods of formulation 
and the ingredients selected are not affecting the stability of drug. High drug content 
also gives the assurance that, a good therapeutic outcome can be expected. 
Table No.22: Percentage drug content 
 
G) Diffusion studies across artificial membrane 
 
Diffusion studies of all the formulations were carried out using artificial 
membrane (cellophane membrane -0.8µm) for 48 hrs. The diffusion studies were 
conducted on all formulations as per given in Table No.12. 
 Formulation Drug content Formulation Drug content  
 Code (%) code (%)  
      
 
 
F0 
 
90.00 
 
F6 
 
89.35 
 
 
 
 
 
 
 
F1 
 
91.50 
 
F7 
 
90.10 
 
 
 
 
 
 
 
F2 
 
93.75 
 
F8 
 
98.0 
 
 
 
 
 
 
 
F3 
 
86.25 
 
F9 
 
98.22 
 
 
 
 
 
 
 
F4 
 
94.28 
 
F10 
 
97.55 
 
 
 
 
 
 
 
F5 
 
95.80 
 
F11 
 
99.01 
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The first formulated batch F0 did not consist of any permeation 
enhancers and in vitro diffusion study revealed that only 27.10 % drug released till 48 
hrs.Thus trials were planned to incorporate a permeation enhancer. Salicylic acid at 
concentrations of 5% (F1), 10% (F2), 15% (F3) and 20% (F4) was tried out. The 
diffusion studies revealed that only 64.18%, 65.10%, 68.34% and 69.10% respectively 
was released in 48 hours. It was clear that salicylic acid has improved the drug 
permeation due to its keratolytic activity. But it was also found that the drug 
permeation was not still complete and further increase in salicylic acid concentration is 
not expected to improve permeation. Hence it was decided to select 15% w/v of 
salicylic acid as the optimum concentration.   
 
 To further improve drug diffusion it was decided to include 2-H- β-CD 
in concentrations of 5% (F5), 7.5% (F6) and 10% (F7) into formulations. The drug 
release and diffusion across membrane was found to improve in presence of 2-HP- β-
CD. At concentration of 5%, 82.40% diffusion in 28th hour was observed. In case of 
F6, 89.0% diffusion was observed at 28th hour. It was also observed that as 
concentration of 2-HP- β-CD increased drug diffusion also improved drastically as 
clear from almost complete drug diffusion of 98.40% release in 20th hour with 7.5% 
concentration.   
 
     Though, inclusion of 2-H-β-CD has improved drug diffusion to 
98.40%, it was observed that the release was found to be complete within 20 hours. 
Therefore to sustain the drug release over an extended period it was decided to include 
a rate controlling polymer ethyl cellulose at concentrations of 0.25% (F8), 0.5% (F9) 
and 0.75% (F10) and 1.0% (F11) into formulations.   The result showed an extended 
and complete drug release of 96.80% at 28th hr. in F8 and 93.0 % till 36th hour in F9.  
In F10, a drug diffusion of 97.20% was observed at 40th hr. And finally when the 
concentration of ethyl cellulose was increased to 1% in F11, a drug diffusion of 98.12 
percent which sustained over a period of 48 hours was achieved.  
 
 The formulation F11 was selected as the optimized nail lacquer 
formulation based on drug diffusion studies. 
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Table No.23: Comparative study and optimization of salicylic acid 
                                                                   concentration 
Time(hr) 
PERCENTAGE DRUG RELEASE (µg/ml) 
F1 F2 F3 F4 
0 0 0 0 0 
2 9.82 11.22 13.35 15.25 
4 10.20 12.05 14.98 16.88 
6 13.28 14.35 16.35 17.22 
8 16.42 17.88 18.85 20.13 
10 26.58 28.95 32.05 30.35 
12 32.45 36.33 40.20 36.15 
16 43.10 42.30 48.38 42.95 
20 48.22 49.98 51.80 50.10 
24 49.65 50.80 52.61 54.32 
28 52.55 54.89 56.80 58.38 
32 56.25 58.75 59.33 60.21 
36 58.95 59.98 61.28 63.45 
40 60.18 62.15 63.92 66.21 
44 62.52 63.25 65.99 68.84 
48 64.18 65.10 68.34 69.10 
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Figure 22: Comparative Dissolution profile of F1 v/s F2 v/s F3 v/s F4 
Table No.24: Comparative study and optimization of 2-HP- β-CD  concentration   
Time(hr) Percentage drug release 
F5 F6 F7 
0 0 0 0 
2 26.25 32.12 39.31 
4 32.23 43.55 49.85 
6 38.51 52.82 59.65 
8 46.52 61.65 67.72 
10 48.22 69.35 76.45 
12 56.28 76.25 85.05 
16 65.15 80.02 92.15 
20 76.45 83.35 98.40 
24 79.92 88.95 96.25 
28 82.40 89.00 94.23 
32 80.25 86.32 93.15 
36 79.45 84.15 91.82 
40 77.31 82.15 90.08 
44 76.65 80.85 89.16 
48 74.72 78.25 88.95 
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Figure 23: Comparative Dissolution profile of F5 v/s F6 v/s F7  
Table No.25: Comparative study and optimization of Ethyl cellulose 
concentration  
Time(hr) PERCENTAGE DRUG RELEASE (µg/ml) 
F8 F9 F10 F11 
0 0 0 0 0 
2 29.65 26.52 19.45 12.82 
4 34.12 31.98 30.45 27.12 
6 45.56 40.43 36.91 28.31 
8 51.16 44.90 48.84 32.72 
10 62.34 53.22 50.74 46.25 
12 69.74 60.13 56.79 50.21 
16 75.93 68.66 60.24 58.65 
20 88.45 72.32 65.71 60.21 
24 93.23 83.45 72.67 68.11 
28 96.81 89.76 80.51 70.22 
32 95.00 95.84 85.72 78.85 
36 94.57 93.78 90.62 84.15 
40 93.14 90.72 97.56 88.85 
44 90.76 89.87 94.22 90.25 
48 89.01 88.73 91.31 98.12 
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Figure 24: Comparative Dissolution profile of F8 v/s F9 v/s F10 v/s F11 
 
H) In vitro ungual permeation studies 
 
To simulate and mimic diffusion study with that of in vivo conditions, i.e. across nail 
plate, a diffusion study across hooves obtained from freshly slaughtered cattle was 
done. There was no significant difference in diffusion and drug release data obtained 
across artificial and hoof’s membrane. This study gives the assurance that a good in 
vitro in vivo correlation can be expected.  
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Table No.26: Comparison of drug diffusion across artificial membrane and 
hoof’s membrane 
Time 
PERCENTAGE DRUG RELEASE (µg/ml) 
  
% drug diffused through 
artificial membrane 
% drug diffused through hoof’s 
membrane 
0 0 0 
2 12.82 14.50 
4 27.12 20.90 
6 28.31 26.45 
8 32.72 36.75 
10 46.25 47.90 
12 50.21 56.72 
16 58.65 60.45 
20 60.20 65.80 
24 68.11 72.55 
28 70.22 80.60 
32 78.85 85.05 
36 84.15 89.25 
40 88.85 92.30 
44 90.25 95.01 
48 98.12 97.45 
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Figure 25: Comparison of drug diffusion across artificial membrane and hoof’s 
membrane 
I) Anti-microbial study 
 
The zone of inhibition for the various formulations was determined, 
and it was found to range from 17-22mm, which is comparable with that of standard 
with 21mm. This indicates that all the formulations were sensitive to the 
microorganism Candida albicans .Results are reported in Table No.26 and Figure:26. 
 
 
 
 
Figure 26: Zone of inhibition of Formulated Nail Lacquers  
 
 
0
10
20
30
40
50
60
70
80
90
100
0 4 8 12 16 20 24 28 32 36 40 44 48
Pe
rc
en
ta
ge
 
 
dr
ug
  r
el
es
ed
  (μ
g/
m
l) 
  
Time  (hr) 
 
 
COMPARISON OF DRUG RELEASE PROFILE FOR F11 
FORMULATION 
THROUGH ARTIFICIAL AND HOOF'S  MEMBRANE 
 
 
Through artificial membrane
Through Hoof's membrane
Results and Discussion 
 
RVS College of Pharmaceutical Sciences Page 76 
  
                          Table No.27: Zone of inhibition of Miconazole nitrate Nail lacquers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J) Stability studies 
                                   Stability studies were used to determine the shelf life and storage 
condition of a product. In this investigation F11 were subjected to accelerated stability 
studies for a period of 1 month. Accelerated stability studies were performed in 
accordance with ICH guidelines with necessary modifications. 
The studies were carried out to verify the changes in physical 
characteristics such as Non -volatile content, Drying time, % drug content, drug 
diffusion at three different conditions of higher temperature (40±20C) for 1 month. The 
results are reported in Table No.28,29.  
 
 
Table No.28: Stability studies data of  F11 
 
Parameter Initial After 
Non-volatile content 36±0.81 35±0.35 
Drying time(sec) 56 58 
Drug content 99.01 98.50 
 
Formulation Zone Of Formulation Zone Of 
Code 
Inhibition 
(mm) code 
Inhibition 
(mm) 
  
  
F1 22 F7 19 
 
 
 
 
F2 18 F8 24 
 
 
 
 
F3 21 F9 17 
 
 
 
 
F4 22 F10 23 
 
 
 
 
F5 17 F11 22 
 
 
 
 
F6 16 Standard 21 
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Table No.29: Invitro Diffusion profile of F11 upon stability studies 
Time 
 
PERCENTAGE DRUG RELEASE (µg/ml) 
Before stability After stability 
0 0 0 
2 12.82 10.60 
4 27.12 24.90 
6 28.31 26.45 
8 32.72 30.25 
10 46.25 39.95 
12 50.21 45.75 
16 58.65 52.55 
20 60.20 58.81 
24 68.11 62.50 
28 70.22 72.05 
32 78.85 76.80 
36 84.15 81.25 
40 88.85 90.53 
44 90.25 92.20 
48 98.12 97.75 
 
 
                  Figure 27:  Invitro Diffusion profile of F11 upon stability studies 
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                                  The evaluation of formulations after stability charging showed 
there was no significant change with respect Non -volatile content, Drying time % 
drug content and drug diffusion with respect to results obtained before stability 
charging. Thus it was concluded that the formulations were found to possess stability 
compliance requirements as per ICH guidelines. 
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7. SUMMARY 
The objective of the present work was to formulate a medicated antifungal nail lacquer 
containing Miconazole nitrate for the treatment of Onychomycosis. Conventional 
treatments for onychomycosis topically can clinically not efficient, as formulations 
must permeate the nail barrier in order to deliver therapeutic levels of active agents to 
the target site. In the present study, nail lacquer containing a keratolytic agent salicylic 
acid and a permeation enhancer (2-Hydroxypropyl)-β-cyclodextrin in different 
concentration are tried out and comparison of extent of drug permeation has been done 
among the same.  
Initially, research work started with a wide and through literature survey followed by 
 Analytical development studies, where identification and determination of 
λmax and preparation of calibration curve was done. Standard curve was 
prepared for determination of Miconazole nitrate in phosphate buffer pH 7.4 at 
223nm straight line equations for calculations were derived. 
 Preformulation studies of drug like determination of solubility, melting 
point and excipient compatibility studies by FT-IR.  
 During Formulation development studies, a total eleven formulations of 
nail lacquer using permeation enhancers (2-Hydroxypropyl)-β-cyclodextrin 
and keratolytic such as Salicylic acid, were prepared using simple mixing 
technique. Various trials with ethyl cellulose as a rate controlling polymer to 
sustain drug release over 48 hours were also tried out  
            Various studies on physicochemical parameters like film formation, 
optimization of salicylic acid concentration, non -volatile content, drying rate, gloss, 
viscosity, smoothness of flow, anti- microbial studies and stability studies were 
evaluated. All the above parameters were checked to find the compliance.  
             In vitro permeation studies were also performed. Studies were carried out using 
artificial membrane and bovine hooves membrane for 48 hrs. to select the best 
formulation.  
              The best optimized formulation was further subjected for accelerated stability 
studies as per ICH conditions of 40±20C for 1 month .The studies were carried out to 
verify the changes in physical characteristics such as Non -volatile content, Drying 
time, % drug content, drug diffusion under influence of temperature while on storage.  
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8. CONCLUSION 
 The purpose of the present investigation was to formulate and evaluate the 
Miconazole nitrate nail lacquer as an ungual drug delivery system for the treatment of 
onychomycosis.  
 Miconazole nitrate was chosen as a model drug, the formulations were prepared with 
permeation enhancers (2-Hydroxypropyl)-β-cyclodextrin and keratolytic agent, 
Salicylic acid. Then, these lacquers were compared for drying time, nonvolatile 
content drug content, drug diffusion and anti -microbial studies.  
 From the FTIR studies, it was concluded that the drug and the excipients used in the 
formulations were compatible with each other.  . 
   All formulations showed good film formation, drying time, smooth flow, and 
required volatile content.  
 Microbial study results proved that the formulations are sensitive to the 
microorganism Candida albicans. 
 The stability tests showed that the formulations were stable at 400c for 1 month. 
 From Invitro ungual permeation study a good invitro in vivo correlation can be 
expected. 
 The results obtained from the in vitro studies indicate that formulation F11 showed a 
complete drug release which sustained over 48 hours. The F11 formulation had 
salicylic acid at concentration of 15% w/v as keratolytic agent and 10% w/v of (2-
Hydroxypropyl)-β-cyclodextrin as permeation enhancer. This indicates that the 
combination of permeation enhancer and keratolytic agent resulted in an improved 
permeation rate and also a complete and sustained drug release.  
 The percentage non-volatile content of F11 formulation was found to be 36 ± 
0.81.The desired amount of non-volatile matter was seen with complete evaporation 
of volatile matter. 
 F11 formulation showed rapid drying rate. 
 The viscosity of F11 formulation was observed as 152.so this formulation was clear 
and glossy. 
 The adhesive strength of F11 formulation compared with marketed sample and it 
possess adequate adhesive strength on applied nail surface. 
Conclusion 
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 99.01% of drug content was found in F11. So a good therapeutic outcome can be 
expected. 
 From Diffusion studies across artificial membrane, the inclusion of 2-
Hydroxypropyl)-β-cyclodextrin to F11 has improved drug diffusion to 98.40%. 
 The formulation F11 was selected as the optimized nail lacquer formulation based on 
drug diffusion studies. 
 Stability study data showed that there was no much change in the values after stability 
test. It was concluded that the formulations were found to possess stability 
compliance requirements as per ICH guidelines. 
 
 From the above studies, it can be concluded that medicated nail lacquers proved 
to be a better tool as a drug delivery system for the ungual drug delivery of an 
antifungal in the treatment of onychomycosis. Apart from treating the nail infections, 
the medicated nail lacquers can be also used for beautification of nails with ease of 
application. This improves patient compliance and acceptability. 
 
Future Prospective 
Though in this study it has been proved that medicated nail lacquers can act as a useful 
tool for the ungual drug delivery of an antifungal in the treatment of onychomycosis, 
further clinical and pharmacokinetic studies are required to explore the potential of this 
system for use in humans. 
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